IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of

Dobbertin — Confirmation No. 2907

Serial No. 10/567,112 — Group Art Unit 1773

Filed March 6, 2007 — Examiner (not Assigned)

For USE OF LAYER CONSISTING OF HYDROPHOBIC, LINEAR OR TWO DIMENSIONAL POLYCYCLIC AROMATICS AS A BARRIER LAYER OR AN ENCAPSULATION AND ELECTRIC COMPONENTS CONSTRUCTED WITH A LAYER OF THIS TYPE AND COMPRISING ORGANIC POLYMERS

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

REQUEST TO CORRECT PUBLISHED APPLICATION

Sir:

Attached are the following:

1) U.S. Patent Publication 2007/0166547

2) A copy of the date-stamped (February 3, 2007) papers filed in the USPTO for the above-identified application (the executed declaration papers were filed March 6, 2007).

The undersigned notes that a substantial portion of the Published U.S. Patent Application contains figures and text which do not pertain to the application papers as filed, and do not pertain to the German PCT application (PCT/DE2004/001775) to which this application claims priority.

It appears a printing error has occurred at the USPTO, and it is requested that the USPTO correct its records for the application and re-publish the application at an early date.

No fees should be due for correcting the application papers as this appears to be an error on the part of the USPTO; however, should any fees be required, the Commissioner is authorized to charge attorney's deposit account 50-2041 (Whitham, Curtis, Christofferson & Cook).

Respectfully submitted,



Michael E. Whitham
Reg. No. 32,635

Whitham, Curtis, Christofferson & Cook, P.C.
11491 Sunset Hills Road, Suite 340
Reston, VA 20190

Tel. (703) 787-9400
Fax. (703) 787-7557

Customer No.: 30743

371

REQUEST FOR EARLY NOTIFICATION OF SERIAL NUMBER

Docket No. 0310277AA In re: ✓ patent/___ trademark application of
DOBERTIN · ROWALSKY; JOHANNES; HECKER
For USE OF A LAYER CONSISTING OF CYANOPHOS, XANES OF 3-DIMENSIONAL POLYCRYSTALLINE STRUCTURES AS ...

✓ 1 Pages in Specification 16 No. of claims [3 independent; 13 dependent]
2 Sheets of Drawings ___ ✓ Abstract ___ Specimens
___ ✓ Transmittal Sheet ___ ✓ Fee Calculation Form
✓ Combined Declaration and Power of Attorney ___ Ver. Stmt/Sm Entity Status
___ Assignment ___ Recordation Form Cover Sheet
✓ Information Disclosure Statement ✓ PTO-1449 and associated art (9 docs.)
___ Priority Document(s) ✓ Other PRELIM AMDT; TRANSMITTAL; WRITTEN OPINION OF ISA; PCT/IB/306 CK # 9743
✓ Fees $1030 Deposit Account No. (if applicable) _____
(1030 filing fee; _____ Assignment charge; _____ Extra Claims fee)

SERIAL NO. _____
Client Matter No. 0310 0277AA Atty:Asst. MEU/LSH

HAND DELIVERED

371

REQUEST FOR EARLY NOTIFICATION OF SERIAL NUMBER

Docket No. 03100277AA In re: ✓ patent/___ trademark application of
DODDERTIN; KOWALSKY; JOHANNES; BECKER

For USE OF A LAYER CONSISTING OF HYDROPHOBIC, LINEAR OR 2-DIMENSIONAL POLYCYCLIC AROMATICS ...

1 Pages in Specification 16 No. of claims [3 independent; 13 dependent]

2 Sheets of Drawings ✓ Abstract ___ Specimens

✓ Transmittal Sheet ✓ Fee Calculation Form

✓ Combined Declaration and Power of Attorney (unsigned) ___ Ver. Stmt/Sm Entity Status

___ Assignment ___ Recordation Form Cover Sheet

✓ Information Disclosure Statement ✓ PTO-1449 and associated art (9 docs.)

___ Priority Document(s) ✓ Other Prelim Amdt; translation; Written opinion of ISA; PCT/IB/306 CK # 9743

✓ Fees $1030 Deposit Account No. (if applicable) ________

(1030 filing fee; ______ Assignment charge; ______ Extra Claims fee)

SERIAL NO. ________________________

Client Matter No. 0310 0277AA Atty:Asst. MEU/LSH

HAND DELIVERED

03100277AA - 371 filing fee

WHITHAM, CURTIS & CHRISTOFFERSON, P.C.
OPERATING ACCOUNT
11491 SUNSET HILLS RD., STE. 340
RESTON, VA 20190

ACCESS NATIONAL BANK.COM
PROGRESSIVE BUSINESS BANKING
RESTON, VA 20191

9743

68-903/560
02

PAY **ONE THOUSAND THIRTY AND 00/100 DOLLARS**

TO THE ORDER OF

DATE 02/03/06

AMOUNT *$1,030.00*

Commissioner of Patents & Trademarks

⑈009743⑈ ⑆056009039⑆ ⑈2674240⑈

FORM PTO-1390 (Modified) (REV 7-2005) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER: 03100277AA

U.S. APPLICATION NO. (If known, see 37 CFR 1.5):

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/DE2004/001775	04 AUGUST 2004	05 AUGUST 2003 & 28 AUGUST 2003

TITLE OF INVENTION

USE OF A LAYER CONSISTING OF HYDROPHOBIC, LINEAR OR TWO-DIMENSIONAL POLYCYCLIC AROMATICS AS A BARRIER LAYER OR AN ENCAPSULATION AND ELECTRIC COMPONENTS CONSTRUCTED WITH A LAYER OF THIS TYPE AND COMPRISING ORGANIC POLYMERS

APPLICANT(S) FOR DO/EO/US

Thomas DOBBERTIN; Wolfgang KOWALSKY; Hans-Hermann JOHANNES; Eike BECKER

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a submission under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a submission under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
   a. ☒ is attached hereto (required only if not communicated by the International Bureau).
   b. ☐ has been communicated by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. ☒ is attached hereto.
   b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 23 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A power of attorney and/or change of address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13*ter*.2 and 37 CFR 1.821 - 1.825.
20. ☐ A second copy of the published International Application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).
22. ☐ Express Mail Label No.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER

23. Other items or information:

Written Opinion of the ISA (Form PCT/ISA/237)
Notification of the Recording of Change (Form PCT/IB/306)

The following fees have been submitted:		CALCULATIONS	PTO USE
24. ☒ Basic national fee	$300	$ $300.00	
25. ☒ Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article	$0	$ $200.00	
All other situations	$200		
26. ☒ Search fee (37 CFR 1.492(b)) If the written opinionof the ISA/US or the International preliminary examination report by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).	$0	$ $400.00	
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the as an International Searching Authority	$100		
International Search Report prepared by an ISA other than the US and provided to the previously communicated to the US by the IB	$400		
All other situations	$500		
TOTAL OF 24, 25 and 26 =		$ $900.00	

☐ Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)).
The fee is $250 for each additional 50 sheets of paper or fraction thereof.

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole	RATE		
23 - 100 =	0 /50 =	0	x $250.00	$ $0.00	

Surcharge of **$130.00** for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)). $ $130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	16 - 20 =	0	x $50.00	$ $0.00	
Independent claims	3 - 3 =	0	x $200.00	$ $0.00	
MULTIPLE DEPENDENT CLAIMS (if applicable) ☐			+ $360.00	$ $0.00	
TOTAL OF ABOVE CALCULATIONS =				$ $1,030.00	
☐ Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.				$ $0.00	
SUBTOTAL =				$ $1,030.00	
Processing fee of **$130.00** for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				$ $0.00	
TOTAL NATIONAL FEE =				$ $1,030.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **$40** per property +				$ $0.00	
TOTAL FEES ENCLOSED =				$ $1,030.00	
				Amount to be	$
				Amount to be	$

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. ☒ A check in the amount of $ **$1,030.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of $ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **50-2041** . A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

Michael E. Whitham
Registration No. 32,635

PLEASE ASSOCIATE THIS APPLICATION WITH CUSTOMER NUMBER

30743

SIGNATURE

Michael E. Whitham
NAME

32,635
REGISTRATION NUMBER

February 3 , 2006
DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of

Serial No. (Not assigned) Group Art Unit (not assigned)

Filed Concurrently herewith as a national stage filing based on PCT/DE2004/001775 Examiner (not assigned)

For USE OF A LAYER CONSISTING OF HYDROPHOBIC, LINEAR OR TWO-DIMENSIONAL POLYCYCLIC AROMATICS AS A BARRIER LAYER OR AN ENCAPSULATION AND ELECTRIC COMPONENTS CONSTRUCTED WITH A LAYER OF THIS TYPE AND COMPRISING ORGANIC POLYMERS

Box Non-Fee Amendment
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

PRELIMINARY AMENDMENT

Sir:

This preliminary amendment is being concurrently filed with a national stage filing made under 35 U.S.C. 371 from PCT/DE2004/001775. Prior to examination on the merits, and for consideration in calculation of the filing fee, please, please amend the above-identified patent application as follows:

Amendments to the Abstract: A revised abstract is presented on page 2 of this amendment.

Amendments to the Specification: begin on page 3 of this amendment.

Amendments to the Claims: Amendments to the claims are indicated by the notation "currently amended" in the listing of claims beginning on page 4 of this paper.

Remarks: The "REMARKS" section begins on page 10 of this paper.

Amendments to the Abstract

Please amend the Abstract to read as follows:

~~The invention relates to an~~ An electric component is constructed with organic layers and including ~~comprising~~ a layer having ~~consisting of~~ a hydrophobic, linear or two-dimensional polycyclic aromatic with between 3 and 12 ring structures, including phthalocyanines containing metal or devoid of metal, which have -H and/or -F, alkyl groups, aryl groups, and/or fluorinated hydrocarbons as residual groups. The layer may be ~~said layer being~~ used as a barrier layer or an encapsulation. This permits in particular hybrid constructions consisting of SM layers and polymer layers to be obtained. In addition a retroactive encapsulation of the component is no longer required.

Amendments to the Specification

Please amend the paragraph bridging pages 5 and 6 to read as follow:

Accordingly, according to the invention, an organic light-emitting diode having a substrate, a first electrode applied to the substrate, at least one electron-injecting and -transporting zone, at least one hole-injecting and transporting zone and a second electrode, is characterized in that the hole-injecting and -transporting zone includes a layer composed of polycyclic aromatics having linear or two-dimensional chains and from 3 to 12 ring structures including metal-containing or metal-free phthalocyanines, which has, as radical groups, -H and/or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons, this layer being in the form of an encapsulation layer.

Listing of the Claims:

The following is a complete listing of all the claims in the application, with an indication of the status of each:

1. (Original) The use of a layer (HIL 1) composed of a hydrophobic, linearly or two-dimensionally polycyclic aromatic having from 3 to 12 ring structures including metal-containing or metal-free phthalocyanines, which have, as radical groups, -H and or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons, as a barrier layer in or as an encapsulation of electrical components constructed with organic layers.

2. (Currently amended) The use as claimed in claim 1, wherein the layer has been formed from a material selected from the group consisting of anthracene, phenanthrene, tetracene, chrysene, pentacene, hexacene, perylene, triphenylene, coronene, m-naphthodianthracene, pyrene, benzopyrene, ovalene, violanthrene, and derivatives of the aforementioned substances, with radical groups -H and/or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons.

3. (Currently amended) The use as claimed in claim 1, wherein the layer is formed from a metal-containing phthalocyanine of the formula:



where M [=] is any of Cu, Zn, Fe, Mn, Co, or Ni[, V = 0, Ti = 0], and each R may be an -H and/or -F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

4. (Currently amended) The use as claimed in claim 1, wherein the layer is formed from a metal-fee phthalocyanine of the formula:



where [M = Cu, Zn, Fe, Mn, Co, Ni, V = 0, Ti = 0, and] each R may be an -H and/or -F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

5. (Currently amended) An organic light-emitting diode having a substrate ~~(1)~~, a first electrode ~~(2)~~ applied to the substrate ~~(1)~~, at least one electron-injecting and-transporting zone (EIL), at least one hole-injecting and -transporting zone (HTL, HIL) and a second electrode ~~(3), characterized in that~~ wherein the hole-injecting and -transporting zone includes a layer ~~(HIL 1)~~ composed of polycyclic aromatics having linear or two-dimensional chains and from 3 to 12 ring structures including metal-containing or metal-free phthalocyanines, which have, as radical groups, -H and/or -F, alkyl groups, aryl groups, and or fluorinated hydrocarbons, said ~~this~~ layer ~~(HIL 1)~~ being in the form of an encapsulation layer.

6. (Currently amended) An organic light-emitting diode having a substrate ~~(1), a to the substrate (1)~~, a cathode ~~(2)~~ applied to the substrate ~~(1)~~, at least one electron-injecting and -transporting zone (EIL), at least one hole-injecting and -transporting zone (HTL, HIL), and a light-transparent anode ~~(3), characterized in that~~ wherein the electron-injecting and -transporting zone (EIL) is constructed with small molecules, and wherein sais electron-injecting and -transporting zone (EIL) ~~that it~~ is adjoined toward the anode ~~(3)~~ by a layer composed of polycyclic aromatics

having linear or two-dimensional chains and from 3 to 12 ring structures including metal-containing or metal-free phthalocyanines, which includes, as radical groups[,] -H and/or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons.

7. (Currently amended) The organic light-emitting diode as claimed in claim 5 or 6, in which the material of the layer is formed from substances of the group consisting of anthracene, phenanthrene, tetracene, chyrsene, pentacene, hexacene, perylene, triphenylene, coronene, m-napthodianthracene, m-anthraceneoditetracene, m-tetracenodipentacene, pyrene, benzopyrene, ovalene, violanthrene and derivatives of the aforemention substances with radical groups -H and/or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons.

8. (Currently amended) The organic light-emitting diode as claimed in claim 5 or 6, in which the layer is formed from a metal-containing phthalocyanine of the formula



where M [ ] is any of Cu, Zn, Fe, Mn, Co, or Ni, [V = 0, Ti = 0,] and each R may be an -H and/or -F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

9. (Currently amended). The organic light-emitting diode as claimed in claim 5 or 6, in which the layer is formed from a metal-free phthalocyanine of the formula



where [M = Cu, Zn, Fe, Mn, Co, Ni, V = 0, Ti = 0, and] each R may be an -H and/or -F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

10. (Currently amended) The organic light-emitting diode as claimed ~~in any one of claims 5 to 9, characterized in that~~ in claim 5 wherein a hole-injecting and -transporting polymer layer (HIL 2) applied from aqueous solution has been applied between the layer (HIL 1) and the second electrode ~~(3)~~.

11. (New) The organic light-emitting diode as claimed in claim 6 in which the material of the layer is formed from substances of the group consisting of anthracene, phenanthrene, tetracene, chyrsene, pentacene, hexacene, perylene, triphenylene, coronene, m-napthodianthracene, m-anthraceneoditetracene, m-tetracenodipentacene, pyrene, benzopyrene, ovalene, violanthrene and derivatives of the aforemention substances with radical groups -H and/or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons.

12. (New) The organic light-emitting diode as claimed in claim 6, in which the layer is formed from a metal-containing phthalocyanine of the formula



where M is any of Cu, Zn, Fe, Mn, Co, or Ni, and each R may be an -H and/or -F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

13. (New) The organic light-emitting diode as claimed in claim 6, in which the layer is formed from a metal-free phthalocyanine of the formula



where each R may be an -H and/or -F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

14. (New) The organic light-emitting diode as claimed in claim 7 wherein a hole-injecting and -transporting polymer layer (HIL 2) applied from aqueous solution

has been applied between the layer (HIL 1) and the second electrode.

15. (New) The organic light-emitting diode as claimed in claim 8 wherein a hole-injecting and -transporting polymer layer (HIL 2) applied from aqueous solution has been applied between the layer (HIL 1) and the second electrode.

16. (New) The organic light-emitting diode as claimed in claim 9 wherein a hole-injecting and -transporting polymer layer (HIL 2) applied from aqueous solution has been applied between the layer (HIL 1) and the second electrode.

REMARKS

The Abstract has been amended to eliminate "legal" language such as "said" and "comprising', and to eliminate references to "the invention". The Abstract should now be in compliance with the U.S. Patent Rules. The specification has been amended to correct a grammatical error. No new matter has been added.

Claims 2-10 have been amended and new claims 11-16 have been added. The application includes claims 1-16. The amendments correct for multiple dependent claim language format, and correct grammatical and spelling errors.

Please proceed to examination on the merits.

Please charge any fees for such provisional petition and any deficiencies in fees and credit any overpayment of fees to Attorney's Deposit Account No. 50-2041.

Respectfully submitted,

Michael E. Whitham
Reg. No. 32,635

Whitham, Curtis & Christofferson, P.C.
11491 Sunset Hills Road, Suite 340
Reston, VA 20190

Tel. (703) 787-9400
Fax. (703) 787-7557

Customer No.: 30743

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. :

U.S. National Serial No. :

Filed :

PCT International Application No. : PCT/DE2004/001775

VERIFICATION OF A TRANSLATION

I, Susan ANTHONY BA, ACIS,

Director of RWS Group Ltd, of Europa House, Marsham Way, Gerrards Cross, Buckinghamshire, England declare:

That the translator responsible for the attached translation is knowledgeable in the German language in which the below identified international application was filed, and that, to the best of RWS Group Ltd knowledge and belief, the English translation of the international application No. PCT/DE2004/001775 is a true and complete translation of the above identified international application as filed.

I hereby declare that all the statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the patent application issued thereon.

Date: February 2, 2006

Signature :

For and on behalf of RWS Group Ltd

Post Office Address : Europa House, Marsham Way,
Gerrards Cross, Buckinghamshire,
England.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International publication date
17 February 2005 (17.02.3005)

PCT

(10) International publication number
WO 2005/015959 A1

(51) International patent classification[7]: H05B 33/14

(21) International application number: PCT/DE2004/001775

(22) International filing date: 4 August 2004 (04.08.2004)

(25) Language of filing: German

(26) Language of publication: German

(30) Data relating to the priority:
103 36 531.1 5 August 2003 (05.08.2003) DE
103 39 629.2 28 August 2003 (28.08.2003) DE

(71) Applicant *(for all designated States except US)*: TECHNISCHE UNIVERSITÄT BRAUNSCHWEIG CAROLO-WILHELMINA [DE/DE]; Pockelsstrasse 14, 38106 Brunswick (DE).

(72) Inventors; and

(75) Inventors/Applicants *(US only)*: DOBBERTIN, Thomas [DE/DE]; Maschplatz 3, 38114 Brunswick (DE).

KOWALSKY, Wolfgang [DE/DE]; Dorothea-Erxleben-Strasse 41 b, 38116 Brunswick (DE). JOHANNES, Hans-Hermann [DE/DE]; Mörickestrasse 10, 38124 Brunswick (DE). BECKER, Eike [DE/DE]; Ützenkamp 1, 38118 Brunswick (DE).

(74) Attorney: LINS, Edgar; Gramm, Lins & Partner GbR, Theodor-Heuss-Str. 1, 38122 Brunswick (DE).

(81) Designated states *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[continued on next page]

As printed

(54) Title: USE OF A LAYER CONSISTING OF HYDROPHOBIC, LINEAR OR TWO-DIMENSIONAL POLYCYCLIC AROMATICS AS A BARRIER LAYER OR AN ENCAPSULATION AND ELECTRIC COMPONENTS CONSTRUCTED WITH A LAYER OF THIS TYPE AND COMPRISING ORGANIC POLYMERS

(54) Bezeichnung: VERWENDUNG EINER SCHICHT AUS HYDROPHOBEN, LINEAR ODER ZWEIDIMENSIONAL POLYZYKLISCHEN AROMATEN ALS SPERRSCHICHT ODER KAPSELUNG UND MIT EINER DERARTIGEN SCHICHT AUFGEBAUTE ELEKTRISCHE BAUELEMENTE MIT ORGANISCHEN POLYMEREN



(57) Abstract: The invention relates to an electric component constructed with organic layers and comprising a layer consisting of a hydrophobic, linear or two-dimensional polycyclic aromatic with between 3 and 12 ring structures, including phthalocyanines containing metal or devoid of metal, which have -H and/or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons as residual groups, said layer being used as a barrier layer or an encapsulation. This permits in particular hybrid constructions consisting of SM layers and polymer layers to be obtained. In addition, a retroactive encapsulation of the component is no longer required.

(57) Zusammenfassung: Für ein mit organischen Schichten aufgebautes elektrisches Bauelement wird eine Schicht aus einem hydrophoben, linear oder zweidimensional polyzyklischen Aromaten mit 3 bis 12 Ringstrukturen, einschließlich metallhaltigen oder metallfreien Phthalocyaninen, die als Restgruppen -H und/oder -F, Alkylgruppen, Arylgruppen und/oder fluorierte Kohlenwasserstoffe aufweisen, als Sperrschicht oder Verkapselung verwendet. Dadurch sind insbesondere Hybridaufbauten aus SM Schichten und Polymerschichten möglich. Ferner kann eine nachträgliche Verkapselung des Bauelements entfallen.

WO 2005/015959 A1

(84) Designated states *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG.)*
- *of inventorship (Rule 4.17(iv)) for the following designation US*

Published

- *With International Search Report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For an explanation of the two-letter codes and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.

Use of a layer consisting of hydrophobic, linear or two-dimensional polycyclic aromatics as a barrier layer or an encapsulation and electric components constructed with a layer of this type and comprising organic polymers

Electrical components constructed from organic material are increasingly being investigated with a view to their possible uses, since they offer advantages over the typically used semiconductor components. For example, it is known that certain organic materials can be excited to emit light by an electrical charge. Numerous structures of OLEDs (organic light-emitting diodes) have therefore already become known. It has been found that the optically active layer is appropriately composed of a plurality of layers, in which case at least one layer is configured specifically for hole formation (hole injection layer, HIL) and for hole conduction (hole transport layer, HTL), and another layer especially for electron release (electron injection layer, EIL), for electron transport (electron transport layer, ETL) and for light emission (emission layer, EML).

The known structure of such OLEDs envisages a glass substrate on which a transparent anode composed of a transparent conducting oxide (TCO) has been formed, for example from indium tin oxide (ITO). To this arrangement are applied in succession, for example, an HIL, HTL, EML, ETL and EIL, and finally a metallic cathode. In this structure, the light is radiated "downward", i.e. through the substrate.

With regard to the material selection, OLEDs of the known type are constructed either only from layers of different small molecules (SM-OLED, small molecule OLED) or from different polymers (PM-OLED). The small molecules are applied in succession to the substrate as

thin layers by vacuum sublimation. In contrast, polymers are processed from a solution (water or organic solvents). In particular, polymer layers offer advantages as the HIL and HTL, since they exhibit good hole transport properties. Known molecules which are suitable as HILs are, for example, anthracene, tetracene and pentacene (cf. EP 0 278 758 B1).

Since the application of the layers composed of small organic molecules is less problematic, but the layers composed of polymers offer advantages for hole conduction, attempts have been made to undertake a combination of these layers. This is possible in the conventional structure of an OLED when the HIL and HTL polymer layers relevant for hole conduction are applied to the anode (composed of ITO) in the wet state and subsequently dried and vacuum-degassed. The subsequent application of the small molecules by vacuum sublimation is then possible without any problems.

In order to enable direct light radiation, attempts are increasingly being made to realize an inverse structure of an OLED in which the metallic cathode is thus applied to any substrate and then the electron-conducting layers are formed first before the hole-conducting layers are applied and concluded with a transparent anode. For this structure, a hybrid technique is not possible, since, in the case of the wet formation of the hole-conducting HTL and HIL layers, the small molecules of the electron-conducting layers would be attacked by the solvent or dispersant from which the polymers for HTL and/or HIL are applied (for example water), and become unusable in terms of their electrical quality; the metallic cathode is also moisture-sensitive and can be destroyed by contact with water.

It is also known that the layers of the OLEDs are highly moisture-prone, so that the OLEDs, after the

application of the second electrode, are encapsulated in such a way that only connections of the electrodes are accessible.

The proneness of organic materials to moisture also constitutes a problem in other electrical components.

The distinction undertaken above between "small molecules" and polymers has been accepted in the technical field and is customary. "Small molecules" are therefore those organic molecules which do not form chains or networks by polymerization.

It is therefore an object of the present invention to eliminate or at least to reduce the restrictions which exist as a result of moisture sensitivity and as a result of diffusion phenomena for the construction of electrical components from organic substances.

Surprisingly, this object is achieved by the use of a layer composed of hydrophobic, linearly or two-dimensionally polycyclic aromatic having from three to twelve ring structures including metal-containing or metal-free phthalocyanines, which have, as radical groups, -H and/or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons, as a barrier layer in or as an encapsulation of electrical components constructed with organic layers.

The present invention is based on the fact that the layers mentioned, especially and preferably composed of pentacene, can be not only a functional layer in the formation of organic electrical components, but unexpectedly has barrier layer properties which enable the corresponding layer to be used as a barrier layer against moisture for the protection of the layers below it and of the metallic cathode.



where M = Cu, Zn, Fe, Mn, Co, Ni, V = O, Ti = O, and each R may be an -H and/or -F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

In all cases, it is preferred when the number of ring structures of the aromatic is between 5 and 10, preferably between 4 and 10, more preferably between 5 and 8.

Owing to the illustrated use of the layer described in detail as a barrier layer or encapsulation, it is possible to construct organic electrical components in which the layer both fulfills an electrical function and has been formed as a barrier layer or as an in situ encapsulation.

Accordingly, according to the invention, an organic light-emitting diode having a substrate, a first electrode applied to the substrate, at least one electron-injecting and -transporting zone, at least one hole-injecting and -transporting zone and a second electrode, is characterized in that the hole-injecting and -transporting zone a layer composed of polycyclic aromatics having linear or two-dimensional chains and from 3 to 12 ring structures including metal-containing or metal-free phthalocyanines, which has, as radical groups, -H and/or -F, alkyl groups, aryl groups and/or

fluorinated hydrocarbons, this layer being in the form of an encapsulation layer.

According to the invention, the layer mentioned not only forms a functional layer but also performs an in situ encapsulation. For this purpose, the layer structure is such that the layer covers all previously constructed, moisture-sensitive layers.

The invention also makes possible an organic light-emitting diode having a substrate, a cathode applied to the substrate, at least one electron-injecting and -transporting zone, at least one hole-injecting and -transporting zone and a light-transparent anode, wherein the electron-injecting and -transporting zone is constructed with small molecules, and it is adjoined toward the anode by a layer composed of polycyclic aromatics having linear or two-dimensional chains and from 3 to 12 ring structures including metal-containing or metal-free phthalocyanines, which, as radical groups, -H and/or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons.

The present invention therefore also enables an organic light-emitting diode (OLED) which has been constructed in a hybrid structure and in which the radiation is "upward", i.e. away from the substrate side. Accordingly, the invention enables an optimized structure of an upward-radiating OLED, since the layer mentioned functions as an efficient barrier layer which prevents the diffusion of water into the layers below it. Accordingly, it is possible to apply with preference to the layer mentioned, toward the anode, an aqueous polymer film, for example composed of PDOT:PSS, in aqueous form as an additional hole-injecting layer, in order to reduce the required operating voltage of the OLED.

Examples of substances from which the layer serving as a barrier layer or encapsulation in accordance with the invention can be formed are:



anthracene



phenanthrene



tetracene



chrysene



pentacene



hexancene



perylene



triphenylene



coronene



m-naphthodianthracene



m-anthracenoditetracane



m-tetracenodipentacene



pyrene



benzopyrene



ovalene



violanlhrene

R = H and/or F and/or alkyl, aryl,
And/or fluorinated hydrocarbons

phthalocyanine

metal-containing



M = Cu, Zn, Fe, Mn, Co, Ni, V=O, Ti=O

metal-free



R = H and/or F and/or alkyl, aryl,
And/or fluorinated hydrocarbons

For the sake of clarity, it should be pointed out that all of the listed molecules of this layer, even when up to 12 ring structures are present in them, are "small molecules" in the sense of this invention, since no polymerization is present.

The invention will be illustrated in detail below with reference to working examples shown in the drawing. The drawing shows:

Figure 1 a schematic structure of an "upward"-emitting OLED with an HIL layer as an encapsulation layer, all layers being in the form of SM layers.

Figure 2 a schematic structure of an OLED with a hybrid structure composed of SM layers and a polymer layer.

The OLEDs shown in Figures 1 and 2 emit upward. They consist of a substrate 1 to which a metal layer has been applied as a cathode 2. A suitable metal layer is magnesium or an alloy composed of LiF/Al.

The cathode 2 is adjoined by an electron-injecting layer EIL which provides free electrons in a known manner. These recombine with holes from the remaining layers illustrated in detail below in an emission layer EML, in which the recombination gives rise to electroluminescence, i.e. light is emitted.

Above the emission layer EML are optionally disposed a plurality of hole-conducting layers HTLs. These are covered by a hole-injecting layer HIL 1 which may be formed from pentacene in the working example shown. This layer is used as an encapsulation layer in that it is formed in the real construction such that it covers the remaining layers below it. HIL 1 is adjoined by a transparent anode 3 which preferably consists of indium tin oxide. The EIL, EML, HTL and HIL 1 layers are formed as thin layers in a known manner and emit light when a positive voltage of sufficient size relative to the cathode 2 is applied to the anode 3. The emission directed upward is illustrated by an arrow in Figure 1.

As a result of the use of the HIL 1 layer as an encapsulation layer, an otherwise necessary subsequent (ex situ) encapsulation of the OLED becomes superfluous. The inventive OLED according to Figure 1 is therefore encapsulated in situ, so that a subsequent encapsulation can be carried out in a substantially simpler manner as a result of the lowered requirements in relation to their permeability toward water vapor.

In the OLED shown in Figure 2, a structure similar in principle is envisaged, the EIL, EML, HTL and HIL 1 layers all consisting of small molecules (as SM layers). Between the HIL 1 layer used as a barrier layer in accordance with the invention and the anode 3, another HIL 2 layer has been applied, which is formed as a polymer layer, for example PDOT. This HIL 2 polymer layer is applied in the wet state but, owing to the barrier layer action of HIL 1, does not damage the moisture-sensitive HTL, EML and EIL layers below it.

The HIL 2 layer enables the working voltage between anode 3 and cathode 2 to be lowered and increases the efficiency of emission, which is also upward in the working example according to Figure 2.

Since the HIL 2 polymer layer is not moisture-sensitive, it is also possible in this working example for the HIL 1 layer to be configured as an encapsulation layer, i.e. to cover the HTL, EML and EIL layers below it.

What is claimed is:

1. The use of a layer (HIL 1) composed of a hydrophobic, linearly or two-dimensionally polycyclic aromatic having from 3 to 12 ring structures including metal-containing or metal-free phthalocyanines, which have, as radical groups, -H and/or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons, as a barrier layer in or as an encapsulation of electrical components constructed with organic layers.

2. The use as claimed in claim 1, wherein the layer has been formed from a material from the group of anthracene, phenanthrene, tetracene, chrysene, pentacene, hexacene, perylene, triphenylene, coronene, m-naphthodianthracene, m-anthracenoditetracene, m-tetracenodipentacene, pyrene, benzopyrene, ovalene, violanthrene and derivatives of the aforementioned substances, with radical groups -H and/or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons.

3. The use as claimed in claim 1, wherein the layer is formed from a metal-containing phthalocyanine of the formula



where M = Cu, Zn, Fe, Mn, Co, Ni, V = O, Ti = O, and each R may be an -H and/or -F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

4. The use as claimed in claim 1, wherein the layer is formed from a metal-free phthalocyanine of the formula



where M = Cu, Zn, Fe, Mn, Co, Ni, V = O, Ti = O, and each R may be an -H and/or -F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

5. An organic light-emitting diode having a substrate (1), a first electrode (2) applied to the substrate (1), at least one electron-injecting and -transporting zone (EIL), at least one hole-injecting and -transporting zone (HTL, HIL) and a second electrode (3), characterized in that the hole-injecting and -transporting zone a layer (HIL 1) composed of polycyclic aromatics having linear or two-dimensional chains and from 3 to 12 ring structures including metal-containing or metal-free phthalocyanines, which have, as radical groups, -H and/or -F, alkyl groups, aryl groups

and/or fluorinated hydrocarbons, this layer (HIL 1) being in the form of an encapsulation layer.

6. An organic light-emitting diode having a substrate (1), a to the substrate (1), a cathode (2) applied to the substrate (1), at least one electron-injecting and -transporting zone (EIL), at least one hole-injecting and -transporting zone (HTL, HIL) and a light-transparent anode (3), characterized in that the electron-injecting and -transporting zone (EIL) is constructed with small molecules, and that it is adjoined toward the anode (3) by a layer composed of polycyclic aromatics having linear or two-dimensional chains and from 3 to 12 ring structures including metal-containing or metal-free phthalocyanines, which, as radical groups, -H and/or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons.

7. The organic light-emitting diode as claimed in claim 5 or 6, in which the material of the layer is formed from the group of anthracene, phenanthrene, tetracene, chrysene, pentacene, hexacene, perylene, triphenylene, coronene, m-naphthodianthracene, m-anthracenoditetracene, m-tetracenodipentacene, pyrene, benzopyrene, ovalene, violanthrene and derivatives of the aforementioned substances with radical groups -H and/or -F, alkyl groups, aryl groups and/or fluorinated hydrocarbons.

8. The organic light-emitting diode as claimed in claim 5 or 6, in which the layer is formed from a metal-containing phthalocyanine of the formula



where M = Cu, Zn, Fe, Mn, Co, Ni, V = O, Ti = O, and each R may be an -H and/or -F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

9. The organic light-emitting diode as claimed in claim 5 or 6, in which the layer is formed from a metal-free phthalocyanine of the formula



where M = Cu, Zn, Fe, Mn, Co, Ni, V = O, Ti = O, and each R may be an -H and/or -F and/or an alkyl

group and/or an aryl group and/or a fluorinated hydrocarbon.

10. The organic light-emitting diode as claimed in one of claims 5 to 9, characterized in that a hole-injecting and -transporting polymer layer (HIL 2) applied from aqueous solution has been applied between the layer (HIL 1) and the second electrode (3).



Fig. 1



Fig. 2

Docket No.
03100277AA

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

USE OF A LAYER CONSISTING OF HYDROPHOBIC, LINEAR OR TWO-DIMENSIONAL POLYCYCLIC AROMATICS AS A BARRIER LAYER OR AN ENCAPSULATION AND ELECTRIC COMPONENTS CONSTRUCTED WITH A LAYER OF THIS TYPE AND COMPRISING ORGANIC POLYMERS

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on **04 AUGUST 2004** as United States Application No. or PCT International Application Number **PCT/DE2004/001775**

and was amended on **concurrently February 3, 2006**

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, or plant breeder's rights certificate(s), or 365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

			Priority Claimed
103 36 531.1 (Number)	**Germany** (Country)	**05 August 2003** (Day/Month/Year Filed)	☒
103 39 629.2 (Number)	**Germany** (Country)	**28 August 2003** (Day/Month/Year Filed)	☒
(Number)	(Country)	(Day/Month/Year Filed)	☒

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)	(Filing Date)
(Application Serial No.)	(Filing Date)
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

PCT/DE2004/001775	4 AUGUST 2004	PENDING
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DE2004/001775

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 H05B33/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 H05B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	US 5 674 597 A (HAMADA YUJI ET AL) 7 October 1997 (1997-10-07) claim 4	5,7-9
X	US 5 698 740 A (OGAWA TADASHI ET AL) 16 December 1997 (1997-12-16) column 16; figure 2	5,7-9
A	EP 0 532 798 A (ASAHI CHEMICAL IND) 24 March 1993 (1993-03-24) the whole document	1-10
A	EP 0 857 007 A (TDK CORP) 5 August 1998 (1998-08-05) figure 1	1-10

☐ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex

* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
14 January 2005	21/01/2005

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl Fax (+31-70) 340-3016	Friebel, F

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/DE2004/001775

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5674597	A	07-10-1997	JP	3249297 B2	21-01-2002
			JP	8031574 A	02-02-1996
US 5698740	A	16-12-1997	JP	3079909 B2	21-08-2000
			JP	7145372 A	06-06-1995
			JP	3169016 B2	21-05-2001
			JP	2000155432 A	06-06-2000
EP 0532798	A	24-03-1993	EP	0532798 A1	24-03-1993
			CA	2051758 A1	19-03-1993
			DE	69115272 D1	18-01-1996
			DE	69115272 T2	17-10-1996
			US	5281489 A	25-01-1994
EP 0857007	A	05-08-1998	DE	69729931 D1	26-08-2004
			EP	0857007 A1	05-08-1998
			US	6285039 B1	04-09-2001
			EP	1342769 A1	10-09-2003
			WO	9808360 A1	26-02-1998
			US	2002038867 A1	04-04-2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of

T. DOBBERTIN et al.

Serial No.: not yet assigned Examiner: not yet assigned

Filing Date: Concurrently Group Art Unit: not yet assigned

For: USE OF A LAYER CONSISTING OF HYDROPHOBIC, LINEAR OR TWO-DIMENSIONAL POLYCYCLIC AROMATICS AS A BARRIER LAYER OR AN ENCAPSULATION AND ELECTRIC COMPONENTS CONSTRUCTED WITH A LAYER OF THIS TYPE AND COMPRISING ORGANIC POLYMERS

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Under the provisions of 37 C.F.R. 1.97 through 1.99 and pursuant to applicant's duty of disclosure under 37 C.F.R. 1.56, applicant respectfully brings the following documents, listed on the attached form PTO-1449, to the attention of the Examiner in charge of the above-identified application.

These citations do not constitute an admission that the references are relevant or material to the claims. They are only cited as constituting related art of which the applicant is aware.

It is respectfully requested that the listed references be considered by the Examiner and formally made of record in this application. Please charge any deficiencies in fees and credit any overpayment of fees to attorney's Deposit Account No. 50-2041.

Respectfully submitted,



Michael E. Whitham
Registration No.: 32,635

Whitham, Curtis Christofferson & Cook,PC
11491 Sunset Hills Road, Suite 340
Reston, Virginia 20190

703-787-9400

Customer No. 30743

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO.
03100277AA	not yet assigned
APPLICANT(S)	
T. DOBBERTIN et al.	
FILING DATE	GROUP ART UNIT
concurrently (February 3, 2006)	not yet assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5674597	10/1997	Fujii et al.			
		5698740	12/1997	Enokida et al.			
		4885211	12/1989	Tang et al.			

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
		WO 02/063698	8/2002	INTERNATIONAL			✓	
		0532798	3/1993	Europe			✓	
		0857007	8/1998	Europe				✓
		0278758	3/1993	Europe			✓	

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

			T. Dobbertin, et al., "Inverted Top-Emitting Organic Light-Emitting Diodes Using Sputter-Deposited Anodes"; Applied Phys. Letters, Vol. 82, No. 2; 1/2003; pp. 284-286.
			T. Mori, et al.; "Improving the Termal Stability of Organic Light-Emitting Diodes by Using a Modified Phthalocyanine Layer"; Appl. Phys. Letters; Vol. 80, No. 21; 5/2002; pp. 3895-3897.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

US 20070166547A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2007/0166547 A1**

Dobbertin et al. (43) **Pub. Date: Jul. 19, 2007**

(54) **USE OF A LAYER CONSISTING OF HYDROPHOBIC LINEAR, OR TWO-DIMENSIONAL POLYCYCLIC AROMATICS AS A BARRIER LAYER OR AN ENCAPSULATION AND ELECTRIC COMPONENTS CONSTRUCTED WITH A LAYER OF THIS TYPE AND COMPRISING ORGANIC POLYMERS**

(76) Inventors: **Thomas Dobbertin**, Regensburg (DE); **Wolfgang Kowalsky**, Braunschweig (DE); **Hans-Hermann Johannes**, Braunschweig (DE); **Elke Becker**, Braunschweig (DE)

Correspondence Address:
WHITHAM, CURTIS & CHRISTOFFERSON & COOK, P.C.
11491 SUNSET HILLS ROAD
SUITE 340
RESTON, VA 20190 (US)

(21) Appl. No.: **10/567,112**

(22) PCT Filed: **Aug. 4, 2004**

(86) PCT No.: **PCT/DE04/01775**

§ 371(c)(1),
(2), (4) Date: **Mar. 6, 2007**

(30) **Foreign Application Priority Data**

Aug. 5, 2003 (DE)..... 10336531.1
Aug. 28, 2003 (DE)..... 10339629.2

Publication Classification

(51) **Int. Cl.**
B32B 9/04 (2006.01)
H01L 29/08 (2006.01)

(52) **U.S. Cl.** **428/411.1**; 257/40

(57) **ABSTRACT**

The invention relates to cyclic bioisosteres of derivatives of a purine system having a general structural formula



where R = Li, Na, K,

R^1—H, —NH_2, —Br, —Cl, —OH, —COOH, B═—N═, —CH═, Z═—CH═, —N═, A═—N═ at B═—N═, Z═—CH—, A═—CH═ at B═—N═, Z═—CH—, A═—CH═ at B═—N═, Z═—N═, A═—CH═ at B═—CH═, Z═—CH═, A═—CH═ at B═—CH═, Z═—N═, and their pharmacologically acceptable salts having a normalizing effect on endocellular processes, in particular, it is capable eliminating endocellular metabolic acidosis and capable of binding excessively formed free radicals, in particular, free-radical forms of oxygen, capable of normalizing the nitrergic mechanisms of the cells, and also capable of interreacting with adenosine-sensitive receptors on the membrane of non-nuclear cells and in nuclei-containing cells to decrease the aggregation of thrombocytes. The compounds according to the invention have hepatoprotective effect and can be used for producing pharmaceutical compositions on their base.





FIG. 1a



FIG. 1b



FIG. 2


Δ pH
0,20
0,15
0,10
0,05
0,00
1
2
3
4
5
6

FIG.3


Δ pH
0,14
0,12
0,10
0,08
0,06
0,04
0,02
0
-0,02
1
2
3
4
5
6

FIG.4


ΔpH_f
0,18
0,16
0,14
0,12
0,10
0,08
0,06
0,04
0,02
0,00
1
2
3

FIG.5


I_B,
mV. 3 min
20 000
15 000
10 000
5 000
0
k
2
15
21
37
0
10⁻⁷
10⁻⁶
10⁻⁵
k₁, M

FIG.6


25 000
20 000
15 000
10 000
5 000
0
0
10^{-11}
10^{-10}
10^{-9}
10^{-8}
K, M

FIG. 7a


20 000
15 000
10 000
5 000
0
0
10^{-6}
10^{-5}
10^{-4}
K M

FIG. 7b


I_H,
mV.3 min
20 000
15 000
10 000
5 000
0
1
2

FIG. 8


A_{SOD},
un/min.g
1,0
0,5
0
50
100
k_i, mkM
1
2
3
4

FIG. 9


C_r
%
40
30
20
10
0
1
2
3
4
10
50
100
k_1, mkM

FIG. 10


A_{K_1}
%
150
100
50
1
2
3
4
0
20
40
60
80
100
120 t, min

FIG. 11


A F, %
150
100
50
0
20
40
60
80
100
120 t, min
1
2
3
4

FIG. 12


A NDO, pmol/mg/hour
0,7
0,6
0,5
0,4
0,3
0,2
0,1
0,0
1
2
3

FIG. 13

USE OF A LAYER CONSISTING OF HYDROPHOBIC LINEAR, OR TWO-DIMENSIONAL POLYCYCLIC AROMATICS AS A BARRIER LAYER OR AN ENCAPSULATION AND ELECTRIC COMPONENTS CONSTRUCTED WITH A LAYER OF THIS TYPE AND COMPRISING ORGANIC POLYMERS

FIELD OF THE INVENTION

[0001] The invention relates to medicine, in particular, to pharmaceutical compositions for treatment of various diseases and, more specifically, the invention relates to the medicinal agents that have an appreciable normalizing effect on endocellular processes, in particular, elimination of an endocellular metabolic acidosis and binding of excessively formed free radicals.

PRIOR ART

[0002] It is well known that the homeostatic parameters providing survival of an organisms and inseparably linked with each other are mainly a content of gases O_2 and CO_2 in blood, a content of electrolytes Na^+, K^+, CL^+, HCO_3^- and acid-base balance of a cell. The content of gases in blood characterizes oxidation-reduction processes in a cell, oxygen being an important participant of the process of oxidation and carbon dioxide being a product of oxidation reactions. Electrolytes make a basis of an exocellular and endocellular medium, a basis for cellular integration for functioning of nervous and muscular tissue.

[0003] The content of hydrogen ions H^+ is an objective characteristic of the acid-base balance: the hydrogen ions provide a bond between the electrolytes and the blood gases through a buffer system ($HCO_3^- — CO_2$). Besides, the activity of the enzymatic systems depends on the content of hydrogen ions H^+: enzymes are usually most active in a narrow rauge of concentration of hydrogen ions. For each enzyme there is a definite range of pH values, in which the enzyme shows the maximum activity, for example, for α-ptyalin and for catalase pH 6.8 to 7.0, for urease pH 7.0 to 7.2, for trypsin pH 7.5 to 8.5; beyond these ranges the activity of enzymes drops down drastically.

[0004] The effect of a change in pH of a medium on the behavior of an enzyme molecule depends, in particular, on the degree of ionization of the COOH— groups of dicarboxylic aminoacids, SH— groups of cysteine, imidazole nitrogen of histidine, NH_2— group of lysine and other groups. At a significant difference of the pH of a medium from the optimal values the enzymes are exposed to conformational changes resulting in a loss of activity owing to a denaturation or a change of the enzyme molecule charge. At different pH values of the medium the active center of the enzyme can be in a partially ionized state or in non-ionized state that adversely affects the tertiary protein structure and, respectively, on the formation of an active enzyme-substrate complex.

[0005] Besides, pH of a medium has an effect on the rate of ionization of substrata and coenzymes.

[0006] For a cell it is important to maintain the acid-base balance, i.e. formation of hydrogen atoms H^+ and their removal from the cell. The absolute or relative increase of a hydrogen ion concentration in a medium makes it acidic and a decrease alkaline. The concentration of H^+ in blood plasma under normal condition of an organism makes about 10^{-7}. The value of pH in blood is very stable and normally varies from pH 7.35 to 7.45. A deviation of pH results in abnormal functioning of the cells and, first of all, of their numerous enzymatic systems, a change of direction and intensity of the oxidation-reduction processes, for example, the ability of haemoglobin to bind and give back oxygen. In this case all metabolic processes and, first of all, aqueous and electrolytic metabolism change, the sensitivity of the cellular receptors is disturbed, the permeability of membranes, nervous-muscle excitability and conduction are changed.

[0007] The physiological systems participate in the maintenance of pH values for normal vital activity of the blood and tissues: lungs, liver, kidneys, gastric path and buffer systems: haemoglobin, bicarbonate, protein and phosphatic. The buffer systems rather quickly and effectively prevent a shift of the acid-base balance but they are not capable to keep it for a long time without participation of the physiological systems.

[0008] When the capability of the above compensatory systems by the maintenance of the hydrogen concentration is exhausted, the acid-base balance is disturbed, in which case two different states can arise: acidosis, when the concentration of hydrogen ions is higher than the optimum concentration (pH is below the optimum value) and alkalosis. A decrease of pH below 6.8 is incompatible to life.

[0009] The metabolic acidosis is the most serious and most frequently encountered form of disorder of the acid-base balance. The metabolic acidosis can be a result of hypoxia of any origin: exogenous, circulatory, respiratory, tissue, hemic, as well as sugar diabetes, starvation, fever, renal failure, long diarrhea, extensive inflammations, for example, peritonitis, overdosage of calcium chloride, and other diseases. The kidneys and liver try to compensate for the acidosis: acido- and ammoniogenesis is activated in the renal canals, if the metabolic acidosis is not a consequence of renal failure, and the reabsorption of bicarbonate in the kidneys is intensified to withdraw it from the liver.

[0010] As a rule, the concentration of ions K^+ in plasma increases due to their replacement from the cells by ions H^+. The protein binds ions H^+ and release ions K^+ and Na^+ in the plasma. The increase of the osmotic pressure of the plasma due to hypernatremia promotes discharge of water from the cells and development of a hyperosmolar syndrome.

[0011] Metabolic acidosis leads to pathological changes: the vessels, as a rule, expand at a moderate decrease of pH and narrow at an evident acidosis; at a decrease of the vascular tone the arterial and venous pressure drop down, the venous return to the heart decreases so that the stroke and minute heart volume decreases. The sensitivity of the myocardiocitus to calcium ions and to adrenaline decreases and this is accompanied by a decrease retractive ability of the myocardium.

[0012] Hyperpotassemia with a content in ions K^+ in the plasma exceeding 5.2 mmol/l entails disorder of the nerve-and-muscle conduction and originates such symptoms as an increased tonus of the transversospinal muscle, vomiting, diarrhea, mental disorder, sensitivity disorder, bradycardia,

extrasystole. When the concentration of ions K^+ in the plasma is higher than 7.5 mmol/l, a development of a ventricular fibrillation of heart and stopping it in the diastole, as well as paralysis of the sceletal musculation are possible. The aggregation and agglutination of thrombocytes rise up and the emerging microthromboses break the microcirculation, aggravating the hypoxia, causing disorder of the metabolic processes and strengthen the acidosis.

[0013] The disorder of the heart activity and peripheral blood circulation result in repeated malfunction of the kidneys, liver, and the central nervous system. In serious cases the coma develops that can lead to stopping the respiration.

[0014] At an excessive decrease of pH in the cell (less than 6.8) the cell lysosomes are destroyed and the cells are subjected to autolysis under the effect of lysosomal enzymes.

[0015] The development of authentic methods of intravital pH-metering of cells has allowed us to determine that the changes in the endocellular pH accompany many major processes on the cellular level. Some factors point to the fact that for normal vital activity of the cells and tissues of an organism the maintenance of pH in a definite range is necessary. A plausible reason may be high sesuitivity of the basic cellular enzymes to the pH value. For example, it is known that the activity of one of the key enzymes of glycolysis 6-phosphofructokinase [2.7.1.11] grows by dozens of times at an increase of pH in a medium by 0.2 units (Trump B. F, Berezesky I. K. "The role of altered $[Ca^{2+}]$ in regulation in apoptosis, oncosis and necrosis". Biochem. Biophys. Acta, 1996, v. 1313, p. 173-178).

[0016] The activity of Pyruvatcarboxylase [6.4.1.1], phosphorylases [2.4.1.1] catalyzing the glycogen metabolism also depends on the pH value, and their activity is inhibited at a rising pH of cytoplasm (Roos A., Boron W. F. "Intracellular pH". Physiol. Rev., 1981, v. 61, p. 296-434).

[0017] It is well known that there is a correlation between processes of attachment of substrate cells, an increase of pH and a start of the mechanism of proliferation of the minimally transformed cells (Akopov V. S., Grobova M. E., Rkshevoi Yu. V. "Endocellular pH and substrate dependence of proliferation of fibroblasts of Chinese hamster". Cytology, 1991, 33 (7), p. 86-94; Gillies R. G., Martinez-Zaguilan R., Peterson E. P., Perona R. "The role of intracellular pH in mammalian cell proliferation". Cell. Physiol. Biochem., 1992, 2, p. 159-179; Akatov V. S., Grobova M. E. "Activation of intracellular pH regulating systems upon cell adhesion to solid substrate". Biol. Membr., 1993, v. 6, p. 917-934).

[0018] It has been found that a decrease of pHi in macrophages inhibits the production of superoxide and phagocytic activity. Besides, the activation of phagocytes results in a protons yield that, in turn, results in rising the pH value (Kapus A., Romanek R., Qu A. Y. Rotstein O. O., Grinstein S. A. "pH-sensitive and voltage-dependent proton conductance in the plasma membrane of macrofages". J. Gen. Physiol., 1993, vol. 02 (4), p. 723-760).

[0019] A change of pHi is considered as a possible mediator of spreading and chemotaxis of neutrophils, and a strict correlation of pHi is necessary for successful fulfillment of the microbiocide function (Demaurex N., Downey G., Waddell T., Grinstein S. "Intracellular pH regulator during spreading of human neutrophils", J. Cell. BioL., 1996, v. 133, p. 1381-1402).

[0020] On the basis of the above data one may make a true conclusion that an increase of endocellular pHi is an indication of activity of cells. Therefore, using the knowledge on the pH value and on ways and methods of maintenance of this parameter in a definite range, it is possible to act on the endocellular processes efficiently.

[0021] For example, in the prior art there are known researches on development of medicinal preparations capable of selectively collecting in the cells of tumors, differing from the normal cells by the pHi value (Tannock I. A.. Rotin D. "Acid pH in tumors and its potential for therapeutic exploration". Cancer Res., 1989, v. 49, p. 4373-4384; Stabbs M., Rodrigues L., Howl F. A., Wang I., Joeng K. S., Veech R. L., Griffiths J. R. "Metabolic consequences of a reversed pH gradient in rat tumors". Cancer Res., 1994, v. 54, p. 4011-4016)

[0022] A possibility of a predicted change of the endocellular pHi has practical importance for regulation of the endocellular metabolism. Therefore, development of pharmaceutical compositions capable of effectively increasing pHi is an urgent task.

[0023] Known in the art is application of ferruginous compounds, including iron citrate and acetate and their combinations in the case of hyperphosphatemia, as a means for decreasing the phosphorus content and for correcting the metabolic acidosis at renal failure (U.S. Pat. No. 5,753,706) on the basis of absorption of absorbed phosphases in an intestine.

[0024] Also known in the art a veterinary composition for treatment or prevention of a lactate acidosis containing alpha-2-adrenoceptor antagonist from the group of imidazolines, benzodioxfinoimidazolines and benzofuquinolines (U.S. Pat. No. 5,196,432).

[0025] Known in the art is a method of protection of human cells against irreversible disorders brought on by a lactate acidosis due to oxygen failure, preferably, cells of the central nervous system, said method comprising introduction into an organism of a non-toxic compound capable of penetrating through the cell membrane or to overcome the hematoencephalic barrier, which can perform a protective buffer function in the cell and tissues, interfering with an increase of the concentration of hydrogen ions while supporting the pH within physiologically acceptable limits (not lower than 6, 8), taken from the group including $N_2C_2H_2SO_3H$, $NH_2—C(NH)NH(CH_2)_2SO_3H$ or $NH_2—C(NH)NH(CH_2)_2SO_3Na$ (U.S. Pat. No. 5,312,839. A).

[0026] Application of derivatives of 1,4-benzoxazine is known as a medicinal agent for treatment of diseases caused by an endocellular acidosis at miocardial ischemia (U.S. Pat. No. 5,597,820, A).

[0027] Known in the art is a drug of hemodynamic action as an aqueous solution of dextran with a molecular weight of 40000 with addition of salts: sodium chloride, potassium chloride, magnesium chloride, calcium chloride and sodium

acetate for normalization of the acid-base balance and electrolytic balance (RU, 2185173, C2) A high concentration of a complex of salts compared to preparations dextran 40 (USA) and dextran 70 (USA) effectively compensates the deficiency of salts of blood and intertissue liquid, and corrects metabolic acidosis more effectively. Presumably, sodium acetate introduced into an organism takes part in the metabolism and the CH_3COO^- anion turns into water and carbon dioxide, and the cation Na^+ reacts with underoxidized acid products of the metabolism and recovers the pH of the medium. However, the recovery of the pH of the medium not always results in irreversible recovery of the pHi of the cell.

[0028] Application of namacite (carbostimuline) containing bicarbonate, salts of magnesium, manganese and zinc and sodium citrate is known and used for integrated correction of metabolic acidosis, the activity of the drug being a result of interaction of carbon dioxide with the enzymatic protein resulting in a change of the enzyme activity with respect to the complex of reactions of a carboxylation and decarboxylation in the tissues; the ions of magnesium, manganese and zinc activate carboxylases, and sodium citrate serves as a substrate for reactions of a cycle of tricarboxylic acids, lipogenesis (RU, 2014077, C1).

[0029] Known in the art is a method of treatment of Alzheimer's disease due to disorder it is beta-amyloid-peptide metabolism which is growing out of the endocellular acidosis, mainly lactate acidosis, or fluctuation of pH from the normal pH value 7.3 and acid endocellular pH between 5.0 and 7.0 comprising administration to the patient of a pharmacologically effective quantity of an alkaline compound or a buffer capable of rising the endocellular pH from 7.0 to a range of 7.1 to 7.4 and to overcome the hematoencephalic barriers to pass through the cellular membrane to reduce the concentration of hydrogen ions and to have pH from 6.8 to 11.4, namely, the compounds from the group of guanidinethane sulfate, guanidinethane of sulfonic acid and other compounds (U.S. Pat. No. 5,723,496).

[0030] Sodium bicarbonate is used to cure various diseases accompanied by evident acidosis, to beat acidosis during surgical interventions. It is also used as antacid agent at hyperoxemia of gastric juices, at a peptic ulcer of a stomach and duodenal intestine. However, during its application it should be kept in mind that its long administration to an organism can result in uncompensated alkalosis accompanied by serious disorders of the acid-base blood condition.

[0031] Known in the art is preparation trisamine, which includes an active material comprising tri-(oxymethyl)aminomethane, being an antiacid of systemic action (U.S. Pat. No. 5,256,660, A). The trisamine is used at the acute and chronic diseases accompanied by metabolic and mixed acidosis. The preparation is applied intravenously as a 3.66% solution. Trisamine binds a plenty of ions H^+ and deduces them with urine, therefore, it is applied only at normal functioning of kidneys. On the other hand, trisamine promotes an increase of the content of ions HCO_3^- in blood. However, trisamine is contraindicative at disorder of excretory function of kidneys and functional disorders of a liver. Since the preparation also initiates respiratory depression, the patients with failure of ventilation of the lungs are treated with it only under conditions of controlled or assisted breathing.

[0032] At present, in the medical practice metabolic acidosis is eliminated in several steps. At the initial step solutions of sodium bicarbonate or trisamine is used.

[0033] At the following step measures are taken for normalization of the hemodynamics and the gas exchange, improvement of the blood microcirculation and metabolic processes in the organism, correction of the electrolytic misbalance to ensure elimination of the reason caused the shift of the acid-base balance.

[0034] Also known in the art is a medicinal preparation <<dimephosphon>>, containing dimethyl ester of 1,1-dimethyl-3-oxybuthyl of phosphonic acid as an active material (Mashkovsky M. D., "Medicinal Agents". Moscow, Medicine, 1993, part II, p. 137-140) whose antiacidotic effect is associated with the activation of metabolic processes, regulation of the acid-base balance of an organism including pneumonia and acute respiratory diseases. However, the application of this drug can cause dyspeptic disorder.

[0035] The development of medicinal preparations eliminating endocellular metabolic acidosis and rendering normalizing effect on the endocellular processes is and actual problem.

DISCLOSURE OF THE INVENTION

[0036] An object of the present invention is to produce a medicinal agent for correction of disorders of endocellular processes.

[0037] Another object of the invention is to provide a medicinal agent based on compounds having biological activity for normalization of the acid-base balance of a cell due to withdrawal from the cell of excessive quantity of protons thereby increasing the cell pH, normalizing the activity of the enzymatic systems, normalizing the direction and intensity of the oxidation-reduction processes through interaction with adenosine-sensitive receptors on the membrane and inside the cell and binding of excessively formed free radicals.

[0038] The biologically active compounds having properties necessary for attaining the above objects are based on derivatives of condensed pyridazinedione systems, which, in the inventors' opinion can have cyclic isosterism with respect to adenosine, because they contain ring systems similar to adenosine by size and character of the electron density.

[0039] The inventors assumed that the condensed pyridazinedione systems having a structure similar to adenosine may have similar reactivity in an organism, are capable of attracting β-D-ribofuranous fragments, and react with receptors sensitive to adenosine and penetrate through the cellular membrane i.e. can be the biological isosteres of adenosine. At the same time, they are electrochemically active compounds with sufficiently low potentials of reduction and can attach 2-4 protons and electrons thus eliminating the endocellular metabolic acidosis.

The object of the invention was attained by providing cyclic bioisosteres of a purine system having a general formula:



[0040] R^1=—H, —NH_2, —Br, —Cl, —COOH,

[0041] B=—N=, —CH=, Z=—CH=, —N=,

[0042] A=—N= at B=—N=, Z=—CH—,

[0043] A=—CH= at B=—N=, Z=—CH—,

[0044] A=—CH= at B=—N=, Z=—N=,

[0045] A=—CH= at B=—CH=, Z=—CH=,

[0046] A=—CH= at B=—CH=, Z=—N=,

and their pharmacologically acceptable salts having a normalizing effect on endocellular processes.

[0047] The derivatives of pyrido[2,3-(d]-6H-pyridazine-5,8-dione, cyclic bioisostere of derivatives of purine system were synthesized and investigated, in which the pyridine ring is condensed with a pyridazinedione ring having a general formula:



in particular:

[0048] sodium salt of 7-(β-O-ribofuranosile)pyrido[2,3-1]-6H-pyridazine-5,8-dione sodium salt (1),

[0049] 4-amino-7-(β-D-ribofuranosile)pyrido[2,3-d]-6H-pyridazine-5,8-dione (2),

[0050] sodium salt of 3-bromine-7-β-B-ribofuranosile)pyrido[2,3-d]-6H-pyridazine-5,8-dione (3),

[0051] disodium salt of 4-hydroxy-7-(βD-ribofuranosile)pyrido[2,3-d]-6H-pyridazine-5,8-dione (4),

[0052] disodium salt of 3-Kap6OKCu-7-(β-D-ribofuranosile)pyrido[2,3-d]-6H-pyridazine-5,8-dione (5),

[0053] lithium salt of pyrido[2,3-d]-6H-pyridazine-5,8-dione (6),

[0054] sodium salt of pyrido[2,3-d]-6H-pyridazine-5,8-dione (7),

[0055] potassium salt of pyrido[2,3-d]-6H-pyridazine-5,8-dione (8).

[0056] There were also synthesized and investigated derivatives of benzo[d]-3H-pyridazine-1,4-dione, cyclic bioisostere of a derivative purine system, in which the benzene ring condensed with pyridazinedione ring having a general formula:



in particular:

[0057] sodium salt of 2-(β-D-ribofuranosile)benzo[d]-3H-pyridazine-1,4-dione (9),

[0058] sodium salt of 5-amino-2-(CP(β-D-ribofuranosile-)benzo[d]-3H-pyridazine-1,4-dione (10),

[0059] sodium salt of 6-amino-2-(β-O-ribofuranosile-)benzo[d]-3H-pyridazine-1,4-dione (11),

[0060] sodium salt of 5-chlorine-2-(β-D-ribofuranosile-)benzo[d]-3H-pyridazine-1,4-dione (12),

[0061] disodium salt of 5-hydroxy-2-(β-D-ribofuranosile-)benzo[d]-3H-pyridazine-1,4-dione (13),

[0062] lithium salt of 5-amino-benzo[d]-3H-pyridazine-1,4-dione (14),

[0063] sodium salt of 5-amino-benzo[d]-3H-pyridazine-1,4-dione (15),

[0064] potassium salt of 6-amino-benzo[d]-3H-pyridazine-1,4-dione (16),

[0065] disodium salt of 5-hydroxy-benzo[d]-3H-pyridazine-1,4-dione (17),

[0066] disodium salt of 6-carboxy-benzo[d]-3H-pyridazine-1,4-dione (18).

[0067] There were also synthesized and studied derivatives of pyrazine[2,3-d]-6H-pyridazine-5,8-dione of cyclic bioisostere of a derivative of a purine system, in which the

pyrazine ring condensed with pyridazinedione, having a general formula:



where R = 

R_1 = —NH_2, Br, —OH, —COOH,

in particular:

[0068] sodium salt of 7-(β-D-ribofuranosile)pyrazine[2,3-C]-6H-pyridazine-5,8-dione (19),

[0069] sodium salt of 2-amino-7-(β-D-ribofuranosile)pyrazine[2,3-C]-6H-pyridazine-5,8-dione (20),

[0070] sodium salt of 3-amino-7-(β-D-ribofuranosile)pyrazine[2,3-d]-6H-pyridazine-5,8-dione (21),

[0071] sodium salt of 3-bromine-7-(β-D-ribofuranosile)pyrazine[2,3-C]-6H-pyridazine-5,8-dione (22),

[0072] disodium salt of 2-hydroxy-7-(β-D-ribofuranosile)pyrazine[2,3-C]-6H-pyridazine-5,8-dione (23),

[0073] disodium salt of 2-carboxy-7-(β-D-ribofuranosile)pyrazine[2,3-d]-6H-pyridazine-5,8-dione (24),

[0074] lithium salt of pyrazine[2,3-d]-6H-pyridazine-5,8-dione (25),

[0075] sodium salt of pyrazine[2,3-d]-6H-pyridazine-5,8-dione (26),

[0076] potassium salt of 3-bromine-pyrazine[2,3-C]-6H-pyridazine-5,8-dione (27),

[0077] sodium salt of 2-amino-pyrazine[2,3-d]-6H-pyridazine-5,8-dione (28).

[0078] There were also synthesized and studied derivatives of pyrimido[4.5-d]-6H-pyridazine-5,8-dione of cyclic bioisostere of a derivative purine system, in which the pyrimidine ring condensed with a pyridazinedione ring having a general formula:



-continued

where R = Li, Na, K atom, 

R^1=—H, —NH_2, —Br, —OH, —COOH,

in particular:

[0079] sodium salt of 7-(□-D-ribofuranosile)pyrimido[4,5-d]-6H-pyridazine-5,8-dione (29),

[0080] sodium salt of 2-amino-7-(β-D-ribofuranosile)pyrimido[4,5-d]-6H-pyridazine-5,8-dione (30),

[0081] sodium salt of 4-amino-7-(β-D-ribofuranosile)pyrimido[4,5-d]-6H-pyridazine-5,8-dione (31),

[0082] sodium salt of 2-bromine-7-(β-D-ribofuranosile)pyrimido[4,5-d]-6H-pyridazine-5,8-dione (32),

[0083] sodium salt of 4-hydroxy-7-(β-D-ribofuranosile)pyrimido[4,5-d]-6H-pyridazine-5,8-dione (33),

[0084] sodium salt of 4-carboxy-7-(β-D-ribofuranosile)pyrimido[4,5-D]-6H-pyridazine-5,8-dione (34),

[0085] lithium salt of pyrimido[4,5-d]-6H-pyridazine-5,8-dione (35), 2-amino-pyrimido[4,5-d]-6H-pyridazine-5,8-dione (36),

[0086] potassium salt of 4-bromine-pyrimido[4,5-D]-6H-pyridazine-5,8-dione (37).

[0087] Compounds 1-8, which are derivatives of pyrido[2,3-d]-6H-pyridazine-5,8-dione, were obtained by condensation of ortho-dicarboxysubstituted pyridines with hydrazine hydrate in an acetic acid medium (Taguchi Hiroshi. "A new fluorometric assay method for quinolinic acid". Analitic Biochemistry, 1983, 131 (1), p. 194-197).

[0088] Compounds 9-18, which are derivatives of benzo[d]-3H-pyridazine-1,4-dione (phthalazine dione), were obtained by condensation of ortho-phthalic acid with hydrazine hydrate in an acetic acid medium (Huntress E. H., Stanley L. N., Parker A. S. "The preparation of 3-Aminophthalhydrazide for use in the Demonstration of Chemiluminescence", J, Am. Chem. Soc., 1994, v. 56, p. 241-242).

[0089] Compounds 19-28, which are derivatives of pyrazine[2,3-d]-6H-pyridazine-5,8-dione, were obtained by condensation of ortho-dicarboxysubstituted pyrazines with hydrazine hydrate in an acetic acid medium (Zyczynska-Baloniak I., Czajka R., Zinkowska E., "Synthesis of Derivatives of 4-Hydroxypyrazine-[2,3-d]pyridazine-1-one. Polish Journal of Chemistry. 1978, v. 52, p. 2461-2465; Kormendy K., Ruff F. "Pyridazines condensed with a Heterorng. III", Acta Chimika Hungarika. 1990, 127 (2), p. 253-262).

[0090] Compounds 29-37, which are derivatives of pyrimido[4,5-d]-6H-pyridazine-5,8-dione, were obtained by condensation of ortho-dicarboxysubstituted pyrimidines with hydrazine hydrate in an acetic acid medium (Yurugi S., Hieda M. "Studies on the synthesis of N-Heterocyclic Compounds". Chemistry. Pharmaceutic Bull., 1972, v. 20 (7), p 1522-1527. ibid., p. 1513-1521).

[0091] The synthesis of these compounds is carried out in a few steps. At the first step the ortho-dicarboxysubstituted heterocycles (pyridine, pyrazine, pyrimidine) or derivatives of phthalic acid with hydrazine hydrate are condensed in an acetic acid medium:





where A, B, Z═NH═, —CH═, R^1═—H, —NH^2, Br—, Cl—, OH, —COOH.

[0092] At the second step sodium, potassium, lithium salts of respective condensed pyridazinedione are obtained by a reaction with respective ethylate:





[0093] At the final step condensation of an appropriate salt with 1-chlorine-2,3,5-tri-O-toluoyl-β-D-ribifuranose is effected in a medium of anhydrous DMFA in the presence of a catalyst. Used as a catalyst is 15-crown-5 in the case of salt Na or syn-cis, anti-cis-dicyclohexane-18-crown-6 in the case of salt K.

[0094] The para-toluoyl protection is removed by sodium salt ethylate.







[0095] The ribosulation of salts of heterocyclic bases is carried out using a common technique:

[0096] Added to a mixture of 1.0 mmol of sodium salt of a heterocyclic base of 1.0 mmol 15-crown-5 in 10.0 ml of dry dimethyl formamide (further DMFA) in an atmosphere of dry argon are drops of 1.0 mmol 1-chlorine-2,3,5-tri-O-toluoyl-β-B-ribofuranose while stirring the mixture. The reaction mass is agitated for 6 to 10 hours at a temperature of 20° C. Then 7.0 ml of 10% solution of $NaHCO_3$ is added and the mixture agitated for 30 minutes at 0° C. 30.0 ml of chloroform is added to the obtained suspension, and the liquid is filtered through Hyflo Super Cel, the organic layer is isolated 10.0 ml of water is used for rinsing, and Na_2SO_4 is dried. The obtained nucleosides are chromatographed on silica gel and $CHCl_3$ is eluated. The yield of nucleosides makes 45-65%.

[0097] The removal of the para-toluoyl protection is effected as follows:

[0098] Solution of 0.32 mmol nucleazide in a mixture of methanol and dioxane in a ratio of 5:1 is cooled to 0° C., mixed with 0.7 ml of 0.1M solution of sodium methylate in methanol and held in an argon atmosphere for 24 hours at a temperature of 6° C. The reaction mass is neutralized by addition DOWEX 50 (H^+) to pH 7.0, the resin is filtered off. The final products are isolated from the filtrate by chroma-

tography on silica gel. The eluent is a mixture of $CHCl_3$ and MeOH in a ratio of 20:1. The yield of the end product makes 66-85%.

[0099] Lithium, sodium and potassium salts were obtained by mixing equimolar quantities of heterocyclic compounds with an aqueous solution of appropriate oxyhydroxides. The distillation of water was effected at a reduced pressure without heating according to the well known method of production of alkaline and alkaline-earth salts of aminodihydrophthalazinedione (RU, 2169139, CL).

[0100] The structure of the synthesized compounds was confirmed by the data of an elemental analysis using the EA-11-08 ("Carlo Erba") device and chromatography-mass spectrometry on a chromatography-mass spectrometer "Adgilent Technologies".

TABLE 1

The results of chromatography-mass spectrometry study and elemental analysis of compounds 1-37 according to the invention

		Found, %			Approximate formula	Calculated, %		
Compound No.	(M + H)+	C	H	N	$C_aH_bN_cO_dMe$	C	H	N
1	295	45.60	3.90	13.12	$C_{12}H_{12}N_4O_6Na$	45.43	3.79	13.25
2	310	43.51	4.08	16.69	$C_{12}H_{13}N_5O_6Na$	43.37	3.92	16.87
3	374	36.30	2.84	10.56	$C_{12}H_{11}BrN_4O_6Na$	36.36	2.78	10.61
4	306	41.20	3.10	12.07	$Cu_{11}N_4O_7Na_2$	41.03	3.13	11.97
5	338	40.87	3.10	12.07	$Cu_{11}N_4O_7Na_2$	41.03	3.13	11.97
6	163	49.65	2.51	24.64	$C_7H_4N_4O2Li$	49.70	2.37	24.85
7	163	45.48	2.24	22.63	$C_7H_4N_4O_2Na$	45.41	2.16	22.70
8	163	41.87	2.12	20.78	$C_7H_4N_4O_2K$	41.79	1.99	20.90
9	294	49.51	4.23	8.72	$C_{14}H_{14}N_2O_6Na$	49.37	4.11	8.86
10	309	47.04	4.28	12.74	$C_{14}H_{14}N_4O_6Na$	47.13	4.23	12.69
11	309	43130	4.44	12.47	$C_{14}H_{14}N_4O_6Na$	47.13	4.23	12.69
12	329	44.55	3.60	8.12	$C_{14}H_{12}ClN_2O_6Na$	47.51	3.42	7.99
13	309	44.18	3.56	7.70	$C_{14}H_{12}N_2O_7Na_2$	44.07	3139	7.91
14	177	52.60	3.12	3.13	$C_8H_6N_2O_2Li$	52.46	3.28	22.95
15	177	48.40	3.20	1.15	$C_8H_6N_2O_2Na$	48.24	3.02	21.11
16	177	44.80	2.87	9137	$C_8H_6N_2O_2K$	44.65	2.79	19.53
17	177	43.24	2.01	12.46	$C_8H_6N_2O_2Na_2$	43.24	1.80	12.61
18	295	43136	1.78	1.14	$C_8H_6N_2O_2Na_2$	43.20	1.60	11.20
19	296	41.70	3.52	17.80	$C_{11}H_{11}N_3O_3Na$	41.51	3.46	17.61
20	311	39.75	3.55	21.12	$C_{11}H_{12}N_4O_3Na$	39.60	3.60	21.73
21	311	39.50	3.60	21.14	$C_{11}H_{12}N_4O_3Na$	39.60	3.60	21.73
22	375	33.40	2.47	14.15	$C_{11}H_{10}BrN_4O_3Na$	33.25	2.52	14.11
23	311	37.20	2.75	5.84	$C_{11}H_{10}N_4O_3Na_2$	37.08	2.81	15.73
24	319	39.68	2.70	15.24	$C_{22}H_{10}N_4O_6Na_2$	39.56	2.75	15.38
25	164	42.47	1.59	3.07	$C_{11}H_9N_4O_3Li$	42.35	1.76	32.94
26	164	38.65	1.50	30.27	$C_{11}H_9N_4O_3Na$	38.71	1.61	30.11
27	243	25.70	0.80	9.84	$C_{11}H_9BrN_4O_3K$	25.62	0.71	19.93
28	179	35.71	2.07	4.68	$C_{11}H_9N_4O_3Na$	35.82	1.99	34.83
29	296	41.56	3.64	7.55	$C_{11}H_{13}N_4O_6Na$	41.51	3.46	17.61
30	311	39.74	3.48	1.20	$C_{11}H_{12}N_4O_6Na$	39.64	3.60	21.02
31	311	39.60	3.72	1.13	$C_{11}H_{12}N_4O_6Na$	39.64	3.60	21.02
32	375	33.20	2.70	4.10	$C_{11}H_{10}BrN_4O_6Na$	33.25	2.52	14.11
33	311	37.00	2.94	5.57	$C_{11}H_{10}N_4O_3Na_2$	37.08	2.81	15.73
34	319	39.60	2.67	5.50	$C_{22}H_{10}N_4O_6Na_2$	39.56	2.75	15.38
35	164	42.30	1.91	3.07	$C_{11}H_9N_4O_3Li$	42.35	1.76	32.94
36	179	35.70	2.12	4.90	$C_{11}H_9N_4O_3Na$	35.82	1.99	34.83
37	243	25.47	0.87	20.06	$C_{11}H_9BrN_4O_3K$	25.62	0.71	19.93

[0101] The synthesized compounds are colorless or yellowish crystalline substances with a melting point higher than 300° C.

[0102] The object of the invention was also attained by developing a pharmaceutical composition according to the invention comprising cyclic bioisosteres of a derivative of a purine system as an active ingredient.

BRIEF DESCRIPTION OF THE DRAWINGS

[0103] The invention is further explained by describing the results of the study of biological activity of cyclic bioisosteres of a derivative of a purine system, according to the invention, not limiting their application and within the set of claims with control to the applied drawings, in which:

[0104] FIG. **1***a* illustrates the calibration curves of dependence of the fluorescence intensity of the fluorescence solutions and the cells of mouse NIH 3T3;

[0105] FIG. **1***b* illustrates the calibration curve for determining pHi in the cells of mouse NIH 3T3;

[0106] FIG. **2**—the dependence of pHi of the cell on pH of the medium;

[0107] FIG. **3**—the dependence of pHi of the cell at a change pH of the medium with blood serum after the administration of the compounds according to the invention into the medium;

[0108] FIG. **4**—the dependence of the cell pHi at a change of pH of the medium with no compounds according to the invention in the medium;

[0109] FIG. 3 the change of the cell pHi at a change in pH of the medium after the administration of the compounds according to the invention;

[0110] FIG. 4—the change of the cell pHi at a change in pH of the medium without blood serum after the administration of the compounds according to the invention into the medium;

[0111] FIG. 5—the change of pH_i of fibroplasts in an attached spread state after the administration of the compounds according to the invention into the medium;

[0112] FIG. 6—the intensity of chemiluminescence I_H of a suspension of erythrocytes after incubation with the compounds according to the invention at 37° C. and at 4° C.;

[0113] FIG. 7a—the intensity of chemiluminescence I_H of a suspension of erythrocytes after incubation with the compounds according to the invention in concentrations of 10^{-11} to 10^{-8} M;

[0114] FIG. 7b –the intensity of chemiluminescence I_H of a suspension of erythrocytes after incubation with the compounds according to the invention and an addition of adenosine;

[0115] FIG. 8—the intensity of chemiluminescence I_H of the spleen cells after incubation with the compounds according to the invention at 37° C. and at 4° C.;

[0116] FIG. 9—the effect of the compounds according to the invention on the superoxidedismutase activity;

[0117] FIG. 10– the effect of the compounds according to the invention on the formation of superoxide-anion radicals in the cells;

[0118] FIG. 11– the effect of the compounds according to the invention on the catalase activity;

[0119] FIG. 12—the effect of the compounds according to the invention on the activity of the peroxidase of erythrocytes;

[0120] FIG. 13—the effects of the compounds according to the invention on the NOC activity.

DESCRIPTION OF THE INVENTION

[0121] From the published data it is known that cyclic hydrazides are either not a subject to polarographic reduction or are reduced in a concentrated acid or alkaline solutions at a sufficiently high potential of the half-wave $E_{1/2}$>1.0 V. (Seo E., Kuwana T. "Polarography of cyclic Hydrazides", J. Electroanal. Chem., 1963, v. 6, p. 417-418; Lund H. "Polarographic and electropreparative reduction of 1(2H)-phthalazines, 2,3-dihydro-1,4 phthalazindiones and related compounds", Coll. Czechoslow. Chem. Com., 1965, v. 30. p. 4237-4249).

[0122] However, the inventors have found that compounds 1-37 according to the invention being salts of alkali metals of cyclic hydrazides are liable to electrochemical reduction at a value of the half-wave potential $E_{1/2}$ from minus 0.09 V to minus 0.2 V.

[0123] For comparison, we may give an example of electrochemical reduction of coenzyme NAD$^+$ effected at $E_{1/2}$=−0.32 V, in which the molecule NAD$^+$ receives two electrons and one proton, the second proton remaining in the medium:

$$NAD^+ + 2H^+ \xleftrightarrow{+2e} NADH + H^+$$

[0124] In flavin coenzymes FAD*, in which an isoalloxazine ring is an active part of the molecule, the reduction at the potential $E_{1/2}$=−0.05 V very often results in connection of two protons and two electrons simultaneously.

[0125] The reduced forms of these coenzymes NADH and FADH transport hydrogen and electrons to the respiratory chain of mitochondrions or others energy distributing membranes.

[0126] The respiratory chain of the mitochondrions includes cytochromes b, c_1, c, a and a_3 in an order of rising the magnitude of their redox potential set under conditions of pH 7.0, t=25° C.:

[0127] b(Fe^{3+}) $E_{1/2}$=+0.07 V, c1(Fe^{3+}) $E_{1/2}$=+0.23 V,

[0128] c(Fe^{3+}) (Fe3+) $E_{1/2}$=+0.25 V,

[0129] a(Fe^{3+}) $E_{1/2}$=+0.29 V, a_3(Fe_{3+}) $E_{1/2}$=+0.55 V

that play an important role in the process of tissue respiration.

[0130] The cytochrome is a terminal section of the respiratory chain—cytochrome oxydase, which performs oxidation of the cytochrome with formation of water. The elementary act is two-electron reduction of one atom of oxygen, when each molecule of oxygen interacts with two electroitransport circuits. In the process of transport of each pairs of electrons, up to 6 protons can collect in intermitochondrial space. A change of the ratio in the amount of protons and electrons can result in disorder of the tissue respiration.

[0131] The inventors have found that each molecule of compounds 1-37 according to the invention is capable of penetrating into the endocellular space and, having redox potential comparable to the potentials of the electrochemical reduction of the above processes, can irreversibly attract up to 4 electrons and protons, thereby promoting the intensifications of the processes of tissue respiration and appreciable decrease of a metabolic endocellular acidosis.

1. Electrochemical Activity of the Compounds According to the Invention.

[0132] The electrochemical activity of the compounds according to the invention has been studied.

[0133] Subjected to study were aqueous solutions of compounds 1, 5, 7, 10, 15, 18, 23, 25, 27, 33, 35, 36 according to the invention with an initial concentration of $1\text{-}10^{-2}$ mol/l and, for comparison, a solution of the <<dimephosphon>> drug of the same concentration was used.

[0134] The study was carried out on a general-purpose polarograph PU-1 with a two-coordinate recorder of the "LKD" type using a three-electrode thermostatically controlled polarographic cell and mercury dripping electrode (MDE) with forced separation of the drop and a dropping period of 0.5 second. A platinum wire was used as an

auxiliary electrode and a saturated calomel electrode (SCE) was used as a control electrode.

[0135] 2.0% solutions of sodium chloride having pH 7.0, 7.2, 7.4, 7.6 were used as a background; the pH values of the background solution were corrected by a solution of sodium hydroxide. The polarographic cell was filled with 5.0 ml of the background solution and for 5 minutes was purged with nitrogen for removing the dissolved oxygen. Then 0.5 ml of solution of the studied substance was added to the background solution, and the polarogram was recorded as a polarographic wave. The concentration of the compounds in the polarographic cell was $9 \cdot 10^{-4}$ M.

[0136] The pH was measured on the pH-meter with an accuracy of ±0.05 pH units. The polarographic measurements were carried out at a temperature of 37° C. The recording of polarograms of the investigated materials was effected under conditions of DC current at a scanning rate of the potential 10.0 mV/s with a active scanning stroke from a potential 0 to −0.5 V and sweep retrace from a −0.5 V to 0. The electric-current sensitivity was 5.0 mkA. The scale by the coordinate of the potentials was 50.0 mV/cm. The values of potentials of the half-wave $E_{1/2}$ of the investigated materials are given with respect to the SCE potential.

[0137] The polarogram parameters such as a limiting current i_{lim} and $E_{1/2}$ were determined by the graphic method. The number of electrons participating in the reaction was calculated on the basis of the analysis of the polarographic wave using the Geirovsky-Ilkovich equation.

[0138] The average values of the parameters of the polarographic wave of the investigated materials at a forward recording trace are presented in Table 2.

TABLE 2

	Parameters of polurograms of the compounds				
		pH			
Compound No.		7.0	7.2	7.4	7.6
1, 5, 7	i, mkA	0.26 ± 0.04	0.31 ± 0.02	0.27 ± 0.03	0.30 ± 0.01
"	$-E_{1/2}$, V	0.11 ± 0.02	0.11 ± 0.03	0.105 ± 0.01	0.105 ± 0.02
10, 15, 18	i, mkA	0.23 ± 0.03	0.30 ± 0.01	0.29 ± 0.02	0.31 ± 0.02
"	$-E_{1/2}$, V	0.092 ± 0.02	0.09 ± 0.01	0.092 ± 0.02	0.09 ± 0.01
23, 25, 27	i, mkA	0.32 ± 0.03	0.33 ± 0.04	0.34 ± 0.03	0.34 ± 0.02
"	$-E_{1/2}$, V	0.16 ± 0.02	0.19 ± 0.02	0.175 ± 0.01	0.16 ± 0.015
33, 35, 36	i, mkA	0.30 ± 0.05	0.26 ± 0.02	0.30 ± 0.03	0.30 ± 0.02
"	$-E_{1/2}$, V	0.08 ± 0.02	0.085± ± 0.015	0.085 ± 0.02	0.09 ± 0.02
Dimesphosphon	i, mkA	0.10 ± 0.03	0.12 ± 0.03	0.11 ± 0.02	0.11 ± 0.02
"	$-E_{1/2}$, V	0.175 ± 0.01	0.17 ± 0.02	0.18 ± 0.01	0.18 ± 0.01

[0139] During experiments it was noticed that, compared to the values of the forward stroke, with a record of the polarograms of reverse stroke the value of the half-wave potential had a higher positive potential by 25.0 mV for compounds 1, 5, 7, by 30.0 mV for compounds 10, 15, 18, by 20.0 mV for compounds 23, 25, 27, by 27.0 mV for compounds 33, 35, 26, and by 50.0 mV for the dimesphosphon drug.

[0140] The given data testify on irreversibility of the process of electrochemical reduction of these compounds.

[0141] The calculation of the number of electrons participating in the reduction reaction was effected using the Geirovsky-Ilkovich equation:

$$E = E_{1/2} - \frac{2.3RT}{nF} lg \frac{i}{i_{lim} - i},$$

where n is the number of electrons,

[0142] i is the current value of the wave current, mkA I_{lim} is the value of the limiting wave current, mkA,

[0143] F is the Faraday number equal to 96500K,

[0144] R is the universal gas constant equal to 8.31

[0145] Jole/mol·K

[0146] T is the temperature, K,

[0147] E, $E_{1/2}$ are the potentials, V.

As a result of these calculation, it has been found that during the reduction:

[0148] for compounds 1, 5, 7 the number of electrons is equal to 3.72,

[0149] for compounds 10, 15, 18—4.09,

[0150] for compounds 23, 25, 27—3.72,

[0151] for compounds 33, 35, 36—3.5,

[0152] for dimephosphone—1.6,

i.e. during the reduction of the investigated compounds according to the invention 4 electrons are consumed, and during the reduction of dimephosphone—2 electrons, so we may conclude that compared to dimephosphon the compounds according to the invention manifest higher ability for irreversible attachment of electrons.

[0153] The biological activity of the compounds according to the invention was studied.

2. Effect of the Compounds According to the Invention on pH of a Cell

[0154] Many pH adjusting are known including Na^+/H^+ interchangers located in the plasmatic membrane, Na-de-

pendent and Na-independent HCO_3^-/Cl^- interchangers increasing the pH_i of the cytosol cell, Cl^-/HCO_3^- interchangers decreasing the pH_i of the cytosol cell, carriers of complexes of ions Na^+ with monocarboxylates, proton pumps H^+-ATF-ases, etc. (Ganz M. B. et all. "Arginin-vasopression enchangers of pH, regulation in the presence of HCO_3^- by stimulating three acid-base transport systems", Nature, 1989, v. 337, p. 648-651) are known.

[0155] In view of similarity of biochemical mechanisms of various types of cells, we may come to a conclusion that if a certain agent changes the endocellular pH_i in a definite type of cells, therefore, in view of similarity of the mechanisms of regulation of pH_i, the same agent will change the pH_i in other types of cells. In particular, if the compounds according to the invention result in a change of pH_i of fibroblasts, they can affect the pH_i of macrophages and neutrophils.

[0156] It is well known that the activation of macrophages is associated with production and extrusion of protons, with activation of the systems of transport of protons from a cell by means of proton pumps. Na^+/H^+ interchangers, systems of transport of sodium bicarbonate (Rogachev B., Hausmann M. J., Julzari R., Weiler H., Holmes C., Falet D., Chaimovitz C., Douvdevani A. "Effect of bicarbonat-based dialysis solution on intracellular pH (pH_i) and TNF-alpha production by peritoneal macrophages, Perit. Dial. Int., 1997, November-December, 17 (6), p. 543-553; Bidani A., Heming T. A. "Effect of concanavalin A on Na^+-dependent and Na^+-independent mechanism for H^+ extrusion in alveolar macrophages", Lung., 1998, 176 (1), p. 25-31; Swallow C. J., Grinstein S., Sudsbury R. A., Rotstein O. D. "Relative roles of Na^+/H^+ exchange and vacuolar-type H^+ ATPases in regulating cytoplasmic pH and Function in murine peritoneal macrophages", J. Cell. Physiol., 1993, 157 (3), p. 453-460)

[0157] For example, the activation of the mechanisms of increasing pH_i of cell cytosol, for example, Na^+/H^+ antiporter is necessary for increasing the activity of neutrophils and their microbicidal activity, because a decrease of the cytosol pH blocks the functional activity of neutrophils.

2.1. Effect of the Compounds According to the Invention on pH_i of Fibroblasts

[0158] The effect of the compounds according to the invention on the endocellular pH_i embyronic fibroblasts of mouse NIH-3T3 supplied by the All-Russian Collection of Cellular Cultures of the Institute of Cytology of the Russian Academy of Sciences St. Petersburg was investigated. The cells were grown in the DMEM (Sigma) medium containing 2.2 g/l of sodium bicarbonate with addition of 80.0 mkg/ml of gentamicin and 10.0% embryonal veal serum at a temperature of 37° C. in an atmosphere containing 5.0% of carbon dioxide. For these experiments use was also made of a medium buffer with 5.0 mM of HEPES and 15.0 mM of sodium bicarbonate without serum or with addition of 5.0% serum. The cells were calculated with the help of a hemocytometer. A share of the dead cells was determined by colouring trypan blue.

[0159] The measurements of the endocellular pH_i were carried out with the help of colorants FDA (Sigma) and BCECF-AM (Calbiochem) on a microspectrofluorimeter by a standard technique (Koshevoy Yu. V., Akatov V. S., Grobova M. E. Microspectrofluorimeter for measuring endocellular pH (micro pH)". Devices and equipment for studies in the field of physical-and-chemical biology and biotechnology. Pushchino, 1990. P. 8-14).

[0160] The cells at a temperature of 37° C. were colored within 5 minutes with 5.0 mkM PDA that before the colouring was prepared from a 10.0 mM solution in acetone by dilution for 30 minutes in a phosphatic buffer to 0.1 mM or 2.0 mkM 1.0 mM solution BCECF-AM in DMSO.

[0161] The two-wave method of determining pH_i was used based on the ratio intensities of fluorescence of the cells on two wavelengths (Akatov V. S. et all). "Endocellular pH and substrate dependence of proliferation of fibroblasts of Chinese hamster, Cytology, 1991, 33 (7), p. 86-94). The fluorescence was excited by light at λ=490 nm, the emission was recorded simultaneously with two photomultipliers on wavelengths λ=535 nm and λ=570 nm. The K-ratio of the fluorescence on two wavelengths was determined with a deduction of the background fluorescence of the medium near the investigated cells for 40-60 individual cells, which are then averaged taking into account the measurement error. A thermostatically controlled table was used that allowed measurements to be conducted at a temperature of 37° C. An account was taken for the photodynamic damage of the pigmented cells during-long-time continuous illumination by excited light. The readings were taken from a section of the preparation exposed to light for not more than 5 minutes.

Calibration of Instruments

[0162] The calibration curves for determining the absolute pH_i values by magnitude K were constructed using the Thomas technique (Thomas J. A., Bushbaum R. N., Zimniak A. w Racker E. "Intracellular pH measurements in Ehrlich ascites tumor cells utilizing spectroscopic probe generated in situ", Biochemistry, 1979, v. 18, p. 2210-2218), for which case the pigmented cells treated for 5-10 minutes with carboxyacidic nigericyn (Calbiochem) at a concentration of 5-10 mkg/ml was placed in a solution with a high content of potassium—130 mM KCl, 1.0 mM $MgCl_2$, 20.0 mM of HEPES) and with pH values from 6.2 to 7.6. The K values were measured in the media with different pH assuming that pH_i of the cells equals to the pH of the medium due to the action of nigericyn, which exchanges potassium ions for protons and at a high content of potassium in the medium counterbalances the pH of the medium and cells. Calibration curves were used based on the fluorescence of same medium with addition of 5.0 mkM of fluorescence or BCFCF were used to the control the stability of the of the instrument readings.

[0163] The correctness of the technique was confirmed in the experiments on measurements of pH values of cells treated with protonofor monencine raising pH of the cells due to replacement of sodium ions by protons, and by determining the dependence of the change of pH_i on the change of the pH of the medium. The pH value of the medium (pH_o) was set in the DMEM medium without serum containing 5 mM of HEPES and 15 mM of sodium bicarbonate, by titration with HCl or KOH. The incubation time of the cells in the medium with a given pH value was effected for at least 10 minutes, and this is a sufficient time for setting balance of the pH_i of the cells with the medium pH (Li J., Eastman A. "Apoptosis in an interleukin-2-

depended cytotoxic T-lymphocyte cell line is associated with intracellular acidification", J. Biol. Chem., 1995, v. 270. p. 3203-3211).

[0164] Shown in the graph of FIG. 1*a* are the calibrating dependencies of value K or the ratio of intensities of fluorescence at 530 and 570 nM of fluorescent solutions having pH in a range of 6.4-7.5 (curves 1), and cells of mouse NIH 3T3, loaded with FDA and placed in solutions containing KCl, nigericine and buffer HEPES in a range of pH 6.5 to 7.5 (curve 2). As it is seen from the graphs, the calibration dependencies for cells NIH 3T3 are displaced to the right for 0.1 pH unit relative to the calibration curves of the fluorescent solutions. The constancy of calibration of the instrument using the fluorescence solutions, was supervised in the course of measurements of the effect of the compounds according to the invention on the pH_i and recalculation of the K values in pH_i for cells loaded with FDA is carried out under curve 2. Within one day the calibration was kept with an accuracy of ±0.05 units pH_i and within a month of work with an accuracy of ±0.1 unit pH.

[0165] On the graph of FIG. 16 calibration for cells loaded with pigment BCECF-AM placed in a solution with KCl, nigericine and buffer HEPES (pH 6.5-7.5) is shown. This calibration dependence was used for determining the pH_i in cells loaded with BCECF-AM. In so doing different pigments are used since it is well known that colored FDA can show pH values of not only cytosol but also mitochondrions while the BCECF-AM is an pH_i, indicator, basically, cytosol.

2.1.1. Estimation of Dependence of pH_i of Fibroblasts on pH of Exocellular Medium.

[0166] The dependence of pH_i of fibroblasts on pH of the medium was studied for estimation of possible effect of the compounds according to the invention due to an increase of pH_i of the cell of the medium.

[0167] The cells were colored by pigment BCECF-AM and pH_i was measured 10 minutes after incubation in the medium with an appropriate pH value.

[0168] The graph in FIG. 2 illustrates the dependence of pH_i of fibroblasts of mice NIH 3T3 on the pH of the medium. The results of the study have shown that in the physiological range of pH from 6.9-7.0 to 7.4-7.5 the optimum for the cellular of processes the pH_i is maintained at a constant level. As the pH of the medium to a value of 6.9, pH_i drops down, and the cells are not capable of maintaining the pH_i level in the optimum physiological range.

[0169] We have also found that at pH of the medium above the optimum physiological range the value of pH_i does not increase but drops down, and this may be explained by inclusion of certain adaptive mechanisms of the cell. Only at sublethal for cells pH values of the medium of about 8.5 or more, the pH_i in a cell rises up to optimum values and higher (pH_i 6.9 to 7.1).

[0170] It is well known that blood serum has growth factors, which can to rise pH_i. To estimate the condition and possibilities of the instrument, and for comparison with the action of the preparation, the effect of serum on the pH_i value of the fibroblasts in a suspension was estimated. For this purpose, the pH_i was measured before addition and 20 minutes after addition of 10% serum. It has been found that after addition of serum the pH_i increased by 0.15 units. In the total of 11 experiments the pH_i value of the fibroblasts in a suspension with serum made 6.94±0.01 (12 measurements), and without serum 6.85±0.01 (14 measurements). The measurements were made using FDA and BCECF-AM.

[0171] As it is known to those skilled in the art, On^+-ionophore monencine initiates strong enter of protons into Na^+ cells and output of protons therefrom and this results in an increase of pH_i. For example, in the cells of mice NSO and NIH-3T3 the administration of 1-5 mkM of monensine within 15-20 minutes initiates an increase of pH_i for 0.2 unit (Solovieva M. E., Akatov V. S., Leshchenko V. V., Kudryavtsev V. A. "The mechanism of destruction of cells of myeloma NS/O in culture". Proceeding of the Russian Academy of Sciences, 1998, 2, p. 194-189) and this is in good agreement with the literature data (Zhu W.-H., Loh T.-T. "Effects of Na^+/H^+ antiport and intracellular pH in the regulation of HL-60 cell apoptosis", Biochim. Biophys. Acta, 1995, v. 1269, p. 122-128). On checking this result it has been found that the addition of 10 mkM of monensine into the medium with serum initiates a rise of pH_i by 0.12 pH unit.

[0172] The obtained results on the effect of serum and monensine on pH_i have proved the reliability of the instrument readings and serve as an landmark for comparison of the effects called by the compounds according to the invention.

2.1.2. Study of the Action of the Compounds According to the Invention on pH_i of Fibroblasts.

[0173] The graph in FIG. 3 illustrates the results of the study of the change of the NIH 3T3 fibroblasts in a growth medium DME containing 10.0% blood serum, (field 1) 20 minutes after addition to this medium of a compound from compounds 7, 15, 18, 23, 35, 36 in different concentrations: 0.02 mkg/ml (field 3), 0.2 mkg/ml (field 4), 2.0 mkg/ml (field 5), 20.0 mkg/ml (field 6), from left to right, respectively; of value ΔpH_i at introduction into the medium of compounds 7, 15, 18, 23, 35, 36 and, for comparison, at introduction into the medium of 10 mkM of monensine (field 2).

[0174] It has been found that the compounds according to the invention at a concentration of 0.02 mkg/ml did not increase pH_i. At a concentration of 20.0 mkg/ml the compounds cause a reliable increase of the growth was on the average 0.05 unit pH_i but was not reliably distinct from zero because of a wide scatter of the results. At a concentration of 0.2 and 2.0 mkg/ml the compounds cause a reliable increase of pH_i the cell cytosol on the average by 0.10 and 0.12 unit of pH_i, respectively, similar to the effect observed when adding serum or monensine.

[0175] On the chart of FIG. 4 there are presented the results of the study of the change of pH_i of the cells 20 minutes after addition of the same compounds at a concentration of 0.02 mkg/ml (field 1 of the chart), 0.2 mkg/ml (field 2), 2.0 mkg/ml (field 3), 20.0 mkg/ml (field 4), 200 mkg/ml (field 5) and 1000 mkg/ml (field 6), respectively, from left to right, during the introduction of a compound 7, 15, 18, 23, 35, 36 into medium DME without blood serum, in the absence of growth factors soluble in the medium, cytokines. Under these conditions the investigated materials at a concentration of 2.0 and 20.0 mkg/ml reliably raised pH_i

on the average by 0.08 unit pH_i, and no effect was found on the pH_i of the compounds according to the invention at a concentration of 0.02, 0.2, 200 and 1000 mkg/ml.

[0176] Shown on the chart of FIG. 5 are the results of the study of the effect of introduction of the compounds according to the invention into the medium at a concentration of 2.0 mkg/ml (field 2) and 20.0 mkg/ml (field 3) on the pH_i of fibroblasts in an attached spread state in field 2 and 3, a change from left to right change, respectively, for compounds 7, 15, 18, 23, 35, 36, and, for comparison, the effect of introduction of 10.0 mkM of monensine (field 1). This study was conducted, because under conditions in vivo fibroblasts are usually attached and spread on the tissue matrix elements. It has been found that in this case the investigated materials at a concentration of 2.0 and 20.0 mkg/ml also result in a reliable rise of pH_i on the average by 0.10 and 0.07 unit pH_i similarly to that observed under the action of monensine.

Couclusions

[0177] The obtained results have shown that in a medium with blood serum in the presence of the growth factors and cytokines, compounds 7, 15, 18, 23, 35, 36 according to the invention cause a reliable increase of pH_i of cytosol of embyronic fibroblasts of mice of line NIH 3T3: at a concentration of 0.2 nkg/ml—on the average 0.1 unit pH and at a concentration of 2.0 mkg/ml—on the average of 0.12 unit pH and do not initiate a change of pH at concentrations of 0.02 and 20.0 mkg/ml. The growth of pH_i caused by the administration of the compounds according to the invention is comparable to that observed under an effect of the growth factors of blood serum or ionophore monensine—a known agent causing an increase of pH_i of cytosol.

[0178] In a medium without blood serum, the compounds according to the invention at a concentration of 2.0 mkg/ml and at a concentration of 20.0 mkg/ml reliably increased the pH_i of fibroblasts of the mouse of line NIH 3T3 on the average by 0.08 unit pH and no reliable effect on pH_i of the compounds according to the invention was found at concentrations 0.02, 0.20, 200 and 1000 mkg/ml.

[0179] The compounds according to the invention at a concentration of 2.0 mkg/ml and at a concentration of 20.0 mkg/ml reliably induced an increase of pH_i of cytosol of the line NIH 3T3 mouse fibroblasts attached to an exocellular matrix, on the average by 0.08 unit pH.

[0180] All compounds according to the invention at a concentration of at least 2.0 mkg/ml did not cause changes of pH of the medium with blood serum, and their effect on the pHi of the fibroblasts is not connected with the change of the medium pH caused by them.

[0181] The addition of the compounds according to the invention at a concentration of to 2.0 mkg/ml to a medium with 10.0% of serum at an initial pH of the medium of 7.2±0.1 did not cause an increase of pH of the medium at measurements with an accuracy of up to 0.03 unit pH.

[0182] Thus, it has been shown that the compounds according to the invention at concentrations of 0.2, 2.0, 20 mkg/ml cause increase of pH_i of cytosol of fibroblasts both in the attached state and in a suspension, irrespective of the growth factors and cytokines of blood serum in the medium. The magnitude of rise of pH_i generated by these compounds is comparable to the magnitude observed at the action of the growth factors of serum or monensine ionophore, i.e. a well known agent increasing the cytoplasm pH.

3. Interaction of the Compounds According to the Invention with Adenosine-Sensitive Receptors.

[0183] During the comparative analysis of the chemical structure of the compounds according to the invention or the derivatives of benzo[d]pyridazinedione, pyrido[2.3-d]pyridazinedione, pyrazino[2.3.2]pyridazinedione and pyrimido [4.5-d]pyridazinedione assumptions were made about cyclic isosterism of these compounds and other derivatives of the purine system: adenine, guanine, hypoxanthine. The analysis of their structure allows one to make a conclusion that all the above listed derivatives are condensed heterocyclic ring compounds having similar distribution of electron density. The Stewart-Brigleb models and the above-described reactions ribolization of the compounds according to the invention convincingly prove that β-d-ribofuranose fragment can join the nitrogen atom of pyridazinedione fragment of any of the listed heterocycles. The obtained information allowed us to assume that the compounds according to the invention may feature a biological activity similar to that of the derivatives of the purine of system, in particular, can have isotropy to adenosine-sensitive receptors, and the available differences in the structure and distribution of the π-electron cloud of molecules allow us to predict the presence of additional biological activity, which is absent in derivatives of the purine system: adenine, guanine, hypoxanthine.

3.1. Interaction of the Compounds According to the Invention with Adenosine-Sensitive Receptors of Thrombocytes.

[0184] One of the examples confirming probable similarity of the structure of the compounds according to the invention with the structure of adenosine is a decrease of aggregation of thrombocytes.

[0185] At present, there is known an insignificant amount of medicinal preparations, such as acetosalicylic acid, dipiridamol, indobufen, pentoxyphiline, clopidogel and ticlopidineis used as means for depressing the aggregation of trobocites and improving microcirculation. Note that their efficiency is not satisfactory in all cases of application, and their use is accompanied by side effects due to the ulcerogenic and hepatotoxic action, allergenic properties and other undesirable effects.

[0186] The compounds according to the invention were studied for the effect of aggregation of thrombocytes induced by a preliminary introduction of a solution of an aggregation inductor with a competing introduction of the compounds according to the invention.

[0187] The aggregation of thrombocytes was studied by the Born method based on determination of the changes in the optical density of plasma enriched with thrombocytes after its incubation with an aggregation inductor.

[0188] Adenozinediphosphoric acid (ADP) was selected as an aggregation inductor, which in fact is an aggregation generator. Use was made of a sample (registration number 885) of the Sigma Diagnostics Company (USA) in final concentration of 10^{-5} M.

[0189] The ADP released from the thrombocytes at the initial step of cellular homeostasis initiates formation of an irreversible conglomerate of platelets and is one of integra-

tors of different ways of increasing the amount of thrombocyte platelet aggregates: a phosphoinositol way, release of calcium, cyclic mononucleotides, activation of calmodulin and other ways.

[0190] The experiments were carried out on male rabbits of the "Chinchilla" breed having a mass of 2.7±0.3 kg. 18-24 hours prior to the experiment they were deprived of feed while preserving free access to water.

[0191] To obtain plasma enriched with thrombocytes, blood was taken from a cut of a marginal vein of the rabbit ear, the sample was stabilized with 3.8% of sodium citrate solution in a ratio of 9:1 and centrifuged at 200 g (1000 rev/min) for 10 minutes. The top supernatant layer enriched with thrombocytes was transferred by an automatic dropper into a silicone test tube and kept at 37° C. The plasma enriched with thrombocytes contained, on the average, 3×108 blood platelets in 1 liter. If this content exceeded the specified 3×108 blood platelets in 1 liter, this sample was diluted to the necessary concentration with plasma deprived of thrombocytes, which was obtained by centrifuging blood at 650 g during 10 minutes.

[0192] The measurements of the optical density of the samples were made on two-channel aggregometer of the "Chronolog" Company (USA). A flask containing 490 mkl of plasma rich with thrombocytes was placed in a device, into which a magnetic agitator covered with Teflon was lowered. The index of maximum amplitude of aggregation (MA) in percent of a fall of the plasma optical density under effect of the aggregation inductor was recorded. The control index MA of plasma was compared with the MA of plasma incubated for 3 minutes with different concentrations of the compounds: from 10^{-3} to 10^{-7} in vitro experiments or with plasma obtained 15, 30, 60 and 120 minutes after intravenous administration of different doses of the compounds in vivo experiments.

[0193] The process of aggregation of thrombocytes was recorded with the help of a computer; on the monitor screen the there were depicted curves reflecting changes of the optical density of the plasma enriched which was taken as a standard 100% compared to the optical density of the non-thrombocyte plasma taken for 0% content of thrombocytes.

3.1.1. The In Vitro Studies.

[0194] Under in vitro conditions a flask was filled with blood plasma enriched with thrombocytes, to which an aggregation inductor ADP was added at a concentration of 10^{-5} M, incubated for 3 minutes, and then the compounds according to the invention were introduced directly into the flask. Their action by aggregation of thrombocytes was studied after 3-minute incubation in a wide range of concentrations from 10^{-3} to 10^{-7} M to minimum concentration of 10^{-7} M not inducing no effect of suppressing the aggregation. The results of thus study are given in Table 3.

TABLE 3

Effect of the compounds according to the invention on the ADF-induced aggregation of thrombocytes o the rabbits in vitro

	MA - fall of optical density of plasma, % to the standard, at a concentration of compounds					
	10^{-3} M		10^{-4} M		10^{-5} M	
Compound	Control	Experience	Control	Experience	Control	Experience
2	60.8 ± 3.4	51.4 ± 2.7*	60.0 ± 2.1	50.4 ± 1.7*	52.5 ± 2.1	48.2 ± 1.0*
4	"	49.2 ± 2.3*	"	50.2 ± 2.0*	"	46.2 ± 3.1*
6	"	50.0 ± 1.9*	"	53.3 ± 2.2*	"	47.4 ± 2.0*
9	"	47.3 ± 2.0*	"	53.1 ± 1.8*	"	41.4 ± 3.4*
10	"	46.2 ± 2.7*	"	48.7 ± 2.4*	"	40.2 ± 4.0*
15	"	44.8 ± 2.8*	"	46.3 ± 1.7*	"	39.8 ± 3.1*
21	"	47.1 ± 3.0*	"	49.2 ± 2.1*	"	41.8 ± 2.4*
25	"	48.2 ± 2.9*	"	48.6 ± 2.0*	"	43.4 ± 3.2*
28	"	49.7 ± 2.3*	"	48.9 ± 2.4*	"	44.2 ± 2.7*
31	"	44.9 ± 2.3*	"	46.7 ± 2.2*	"	39.9 ± 2.1*
36	"	45.8 ± 2.3*	"	46.9 ± 2.4*	"	40.1 ± 2.0*
37	"	46.9 ± 2.7*	"	47.1 ± 2.0*	"	40.6 ± 1.7*

	MA - drop of optical density, % compared to control, at a concentration of compounds			
	10^{-6} M		10^{-7} M	
Compound	Control	Experience	Control	Experience
2	52.8 ± 1.8	50.1 ± 2.0	51.5 ± 2.1	50.8 ± 2.2
4	"	50.6 ± 3.1	"	49.9 ± 3.4
6	"	51.2 ± 3.2	"	50.7 ± 3.2
9	"	49.4 ± 3.2	"	51.2 ± 1.7
10	"	48.4 ± 2.4	"	49.8 ± 2.0
15	"	47.3 ± 1.8*	"	49.3 ± 1.4
21	"	49.6 ± 1.7	"	49.7 ± 2.1
25	"	50.3 ± 2.1	"	50.1 ± 3.0

TABLE 3-continued

Effect of the compounds according to the invention on the ADP-induced aggregation of thrombocytes o the rabbits in vitro

28	"	50.9 d 2.7	"	50.4 ± 3.0
31	"	47.5 ± 1.7*	"	49.5 ± 1.2
36	"	49.3 ± 2.6	"	49.7 ± 1.8
37	"	48.1 ± 2.9	"	50.1 ± 1.0

Note:
*valid at $p \leq 0.05$

[0195] From the data given in Table 3 it is evident that on the ADP model of the induced aggregations of thrombocytes the administration of the compounds according to the invention at a concentration of 10^{-3} M initiates a drop of the plasma optical density in a range of 5.4% to 36.5% compared to the control. When introducing the compounds at a concentration of 10^{-4} M, the effect makes 4.0% to 29.2%. The administration of the compounds according to the invention into plasma enriched with thrombocytes at a concentration of 10^{-5} M, results in depression of the aggregative function of the blood platelets and drop of the optical density by 2.3 to 34.1% compared to the control. Thus, in a range of concentrations 10^{-3} M, 10^{-4} M, 10^{-5} M the investigated compounds according to the invention has manifested approximately the same degree of suppression of the aggregation.

[0196] A lower concentration of the compounds in the order of 10 to 6 M reduced the aggregation in a significantly shorter range—from 3.4% to 17.2%. In a concentration of 10^{-} M the action of the compounds stopped.

[0197] The data obtained in vitro indicate to a high anti-aggregative capability of the compounds according to the invention in a range of concentration from 10^{-3} M to 10^{-5}M.

3.1.2. Investigations In Vivo.

[0198] The antiaggregative capability of compounds 2, 15, 21, 37, according to the invention was tested in experiments in vivo. Introduced to the test animals intravenously were an aggregation inductor ADP at a concentration of 10^{-5} M was and then the compounds according to the invention. The doses of the compounds were in a range from 15 to 60 mg/kg. These doses were chosen taking into account the most effective concentration from 10^{-3} M to 10^{-5} M obtained in the experiments in vitro and stipulated by morphological and functional features of the rabbit organism, such as the rate of biotransformation of the drugs, the ratio of the size of the liver to the whole organism, the filtering capacity of the kidneys, etc.

[0199] For leveling the different effects of the compounds in different days due the ambient temperature, humidity and other parameters, 2 animals of each series were taken for experiments every day. Under "series" there is understood a group of 6 animals used for studying one of the doses of the compounds.

[0200] The blood for obtaining plasma enriched with thrombocytes was taken from marginal vein of the rabbit ear: in the control group—directly before introducing the tested compounds; in investigated groups—15 minutes after introducing these compounds and then after 30, 60, 120 minutes and so on up to the moment when the effect of suppression of aggregation disappeared.

[0201] The quantity of thrombocytes was counted before the experiment and at the end thereof in each plasma sample. The results of the experiments are presented in Table 4.

TABLE 4

Effect of the compounds according to the invention on ADP-induced aggregation of thrombocytes of the rabbits (MA - drop of optical density, % to the control)

MA, %, Control	Compound	Dose, mg/kg	MA, %, After 15 minutes	MA, %, After 30 minutes	MA, %, After 60 minutes	MA, %, After 120 minutes
50.1 ± 1.7	2	15.0	44.2 ± 2.0*	42.2 ± 1.6*	46.9 ± 1.7*	49.2 ± 2.0
"	15		42.8 ± 1.8*	41.8 ± 1.5*	45.6 ± 1.5*	48.3 ± 2.3*
"	21		43.5 ± 1.7*	43.3 ± 1.7*	46.7 ± 1.5*	49.1 ± 1.7
"	37		42.9 ± 1.6*	41.9 ± 1.6*	45.9 ± 1.6	48.7 ± 2.1
61.0 ± 1.3	2	30.0	45.3 ± 2.0*	43.7 ± 1.7*	49.1 ± 2.2*	59.7 ± 2.2
"	15		43.2 ± 2.2*	41.8 ± 1.9*	37.8 ± 1.8*	58.1 ± 1.7
"	21		46.7 ± 1.9*	45.4 ± 1.8*	45.0 ± 1.9	60.3 ± 2.1
"	37		43.5 ± 2.0*	42.0 ± 1.4*	41.6 ± 1.4*	58.4 ± 1.7
48.6 ± 1.3	2	60.0	45.2 ± 1.2*	43.6 ± 2.0*	47.8 ± 1.5	48.0 ± 1.2
"	15		43.1 ± 1.5*	41.3 ± 1.5*	44.7 ± 0.8	47.2 ± 1.6
"	21		45.1 ± 0.9*	43.2 ± 2.0*	47.3 ± 1.6	48.3 ± 1.5
"	37		43.4 ± 1.8*	42.4 ± 0.7*	46.2 ± 2.0	47.3 ± 1.7

Note:
*valid at at $p \geq 0.05$

[0202] From the data given in Table 4 it is evident that compounds 2, 15, 21, 37 according to the invention in a dose of 30 mg/kg within 15 minutes after the administration suppressed the aggregation of thrombocytes: a decrease of the value of drop of the optical density MA made 17.5% to 34/9% compared to the control. This effect was maintained at the achieved level 15 minutes longer, and then intensified to the 60th minute from the beginning of the experiment. The recovery of the initial value MA was recorded to the end of the observation upon expiration of 120 minutes.

[0203] During an increase of the dose to 60 mg/kg a similar picture was observed, though the ability of thrombocytes to patching (MA) was reduced to a range of 1.7% to 17.5% compared to the control. The effect of decrease of the aggregation after 30 minutes of experiment was maintained in a range of 3.5 to 20.1% and disappeared to the 120th minute of observation.

[0204] The dose of 15 mg/kg decreased the action of the aggregation inductor in a range of 6.8 to 23% within the first 30 minutes of the experiment. The effect of decrease of the aggregation disappeared to the 120th minute of the experiment.

Conclusions

[0205] The results of the conducted investigations have confirmed the fact that the compounds according to the invention at intravenous administration in doses of 15, 30, 60 mg/kg have evident antiaggregative effect whose duration is about 2 hours.

3.2. Interaction of the Compounds According to the Invention with Adenosine-Sensitive Receptors of Erythrocytes.

[0206] The interaction of compounds 2, 15, 21, 37 according to the invention with adenosine-sensitive receptors of erythrocytes of female mice of line BALB/c of an age of 8-12 months was investigated.

[0207] The dependence of the chemiluminescence intensity of the compounds according to the invention in an alkaline solution of 0.1N NaOH was determined in the presence of hydrogen peroxide being an initiator of chemiluminescence. The chemiluminescence was studied using the <<LKB>> chemiluminometer.

[0208] The erythrocytes of peripheral blood of the mice at first were washed three times by a normal physiological solution with centrifuging and then diluted in the Henks solution without glucose by 10 volumes of distilled water immediately used in the experiment.

[0209] At the first stage of the experiments the washed erythrocytes were incubated at a temperature of 37° C. or at 4° C. with solutions of the compounds according to the invention at a concentration of 10^{-7} to 10^{-5} M for 5-30 minutes, then washed by a normal physiological solution with repeated centrifuging in the cold. The obtained suspension of erythrocytes with the bound compounds according to the invention was placed in 0.1N solution of NaOH with addition of hydrogen peroxide at a final concentration of 10 M. The chemiluminescence intensity was measured. A suspension of erythrocytes without compounds according to the invention was used as a control medium.

[0210] The results of the experiments are presented on the chart in FIG. 6, where the values of chemiluminescence intensity I_H in the suspension of erythrocytes are given: in the control medium (line <<k>>) at an incubation temperature of 37° C. (continuous lines on the chart) and 4° C. (dotted lines on the chart) and the same in the experiments after incubation with the investigated compounds (from left to right for compounds 2, 15, 21, 37), at 37° C. (continuous lines) and at 4° C. (dotted lines) at a concentration of K, from 10^{-7} M, 10^{-6} M and 10^{-5} M. The results have shown that the bond of the compounds according to the invention with the erythrocytes of peripheral blood of the mice does not depend on the temperature, and this, according to the published data, meets the conditions of receptor bonding.

[0211] At the second stage of the experiments the washed erythrocytes were incubated at a temperature of 37° C. with solutions of the compounds according to the invention at a concentration of 10^{-11} to 10^{-8}M during

[0212] 5-30 minutes, then washed twice with a normal physiological solution by centrifuging in the cold, the obtained suspension was mixed with an adenosine solution at a concentration of 10^{-6} to 10^{-4} and incubated for 15 minutes, then washed twice with a normal physiological solution with centrifugiug in the cold. The obtained suspension of erythrocytes with the compounds according to the invention was placed in 0.1N solution of NaOH with addition of hydrogen peroxide in the final concentration of 10^{-7} M. The chemiluminescence intensity was measured. The results of the experiments are presented in FIGS. 7*a* and 7*b*.

[0213] The chart 7a illustrates the value of chemiluminescence intensity I_H during 3 minutes in the control solution (field 0) and after incubation of the erythrocytes with compounds 2, 15, 21, 37 according to the invention (on the chart in the fields from left to right, respectively) at 37° C. at a concentration of the compounds from 10^{-11} M to 10^{-8} M.

[0214] The chart 7b illustrates the chemiluminescence intensity I_H during 3 minutes after incubation of erythrocytes with compounds 2, 15, 21, 37 (from left to right in the fields) at a temperature of 37° C. (field 0) and with addition of adenosine at a concentration of 10^{-6} M, 10^{-5} M and 10^{-4} M.

[0215] As it is evident from the obtained data, the adenosine at a concentration of 10^{-6} to 10 M decreases the bonds of the compounds according to the invention with erythrocytes by a factor of 1.5 that can be a result of competitive honding with receptors of the same type.

Conclusions

[0216] Thus, it has been shown that the compounds according to the invention manifest isotropy to adenosine receptors being on both thrombocytes and erythrocytes.

3.3. Interaction of the Compounds According to the Invention with Nuclei-Containing Cells.

[0217] The features of interaction of the compounds according to the invention with nuclei-containing cells on an example of spleen cells of mice line BALB/c at the age of 8-12 months were investigated.

[0218] The spleen cells were cleaned and washed by centrifuging and suspended in the Henks solution. Then the spleen cells were incubated with compounds 6, 15, 25, 37 at a final concentration of 10^{-5} M for 30 minutes at a temperature of 37° C. or 4° C., then washed twice by centrifuging in the cold. After that the chemiluminescence study was effected on the <<LKB>> luminescence meter as described above.

[0219] The obtained results are illustrated by the chart in FIG. **8**, where in the field 1 there is shown the chemiluminescence intensity I_H of the spleen cells incubated at a temperature of 37° C. without test compounds (control, the first value to the left) and spleen cells incubated with compounds according to the invention (from left to right starting from the second value, respectively, for compounds 6, 15, 25 and 37), and in the field of 2 the chemiluminescence intensity is shown for similar groups of cells and in the same order, incubated at 4° C.

[0220] From the chart of FIG. **8** one may make a conclusion that in the nuclei-containing spleen cells, to which the compounds according to the invention are added at a temperature of 37° C., the luminescence level is much higher, than at 4° C. that is evidence of infiltration of these compounds through cellular membrane into the cell cytosol and their bonding with adenosine-sensitive receptors being inside the cell.

Conclusion

[0221] The results of the investigations allow us to make a conclusion that the compounds according to the invention are biological isosteres of derivatives of a purine system, in particular, adenosine. The compounds according to the invention are capable of attaching the β-D-ribofuranosic fragment and have a chemical structure similar to adenosine. The compounds can interact with adenine-sensitive receptors lying on the membranes of non-nuclear cells, and can penetrate through the membranes of nuclei-containing cells. These properties of the compounds according to the invention give rise to a possibility of effecting adenosine-dependent enzymes performing the functions, for example, inherent in nicotineamide coenzymes such as nicotineamidedeninnucleotide NAD$^+$ and its phosphorylated derivative NADPh$^+$ or flavin-dependent coenzymes FAD$^+$ being important biological carriers of hydrogen atoms.

4. Effect of the Compounds According to the Invention on Hemostasis.

[0222] It is well known that the normally functioning hemostasis system must preserve the liquid state of blood within the vessels that is provided by the powerful anticoagulative blood system and fast thrombosing of the injured sections to prevent hemorrhage and intramuscular hemorrhage. This is aided by some factors of blood plasma, thrombocytes and tissues.

[0223] It is assumed that a living organism has specific inhibitors for each factor of blood coagulation. A decrease of the activity of these inhibitors increases the blood coagulation and promotes formation of thrombuses. An increase of the activity of these inhibitors hampers the blood coagulation and can be accompanied by development of hemorrhage.

[0224] The compounds according to the invention were tested for their effect on the blood plasma factors, in particular, on the plasma hemostasis condition.

[0225] The investigations were performed on 72 rabbits of the "Chinchilla" breed with a mass of 2.5±0.3 kg, who were administered which solutions of compounds 2, 15, 21, 37 in doses of 15, 30 and 60 mg/kg intravenously. The experiments included the thrombin-test (series No. 7300) and the coagulability-test (series No. 5000) purchased from the scientific-and-production association (SPA) "Reuam", thromboplastin (series No. 240600) and calcium chloride purchased from the SPA "MedioLab"

[0226] The static parameters of the blood and plasma coagulation (partial acrivated thromboplastin time, thrombin time, maximum coagulation activity (test for auto coagulation) were determined using the Behnk Electronic coagulometer (Germany). The operating principle of this instrument is based on the fact that the formed blood clot breaks the contacts of the pulse counter in the flask-pin circuit, said pin permanently oscillating in a vertical plane. The moment of formation of the clot is registered by stopping the stop watch hand.

[0227] The measurements were effected at a constant temperature of 37° C. maintained by a temperature control unit.

4.1. The Effect on Partial Activated Thromboplastin Time (PATT).

[0228] The PATT is a standard coagulation sample sensitive to deficiency of all plasma factors (except for VII) specifying the condition of the initial stage of the internal coagulation mechanism and indicating to the presence in the blood of substances having anticoagulation properties, for example, those of heparin.

[0229] Compounds 2, 15, 21, 37 according to the invention at a concentration of 15, 30 and 60 mg/kg were introduced to the above experimental animals intravenously, and their blood samples were taken off 15, 30, 60 and 120 minutes after the administration.

[0230] The blood plasma samples deprived of thrombocytes obtained as described above in an amount of 0.1 ml were put in a coagulometer flask and heated for 1 minute at 37° C., then 0.1 ml of 0.277% solution of calcium chloride was added and the blood clotting time was registered. The coagulation time T in seconds of the control plasma and plasma obtained after intravenous administration after 15, 30, 60 and 120 minutes were compared. The results of the measurements are given in Table 5.

TABLE 5

Effect of the compounds according to the invention on the indexes of PATT of rabbits for intravenous administration

T, s Control	Compound	Dose, mg/kg	T, s after 15 minutes.	T, s after 30 minutes	T, s after 60 minutes.	T, s after 120 minutes
37.0 ± 0.2	2	15.0	37.0 ± 0.1	37.0 ± 0.2	36.9 ± 0.1	37.0 ± 0.3
"	15	"	37.0 ± 0.1	37.0 ± 0.2	36.9 ± 0.1	37.0 ± 0.3
"	21	"	37.1 ± 0.1	37.2 ± 0.1	36.9 ± 0.1	37.0 ± 0.2
"	37	"	37.0 ± 0.2	37.1 ± 0.1	37.0 ± 0.2	36.9 ± 0.1
33.3 ± 0.8	2	30.0	32.7 ± 0.5	32.0 ± 0.1	32.2 ± 0.1	32.1 ± 0.2
"	15	"	32.9 ± 0.8	32.1 ± 0.1	32.0 ± 0.2	32.0 ± 0.1
"	21	"	32.8 ± 0.4	32.0 ± 0.1	32.2 ± 0.1	32.1 ± 0.1
"	37	"	33.1 ± 0.1	33.3 ± 0.1	33.3 ± 0.2	33.0 ± 0.4
32.5 ± 0 3	2	60.0	32.3 ± 0.2	32.4 ± 0.1	32.3 ± 0.1	32.4 ± 0.1
"	15	"	32.2 ± 0.1	32.2 ± 0.1	32.1 ± 0.2	32.2 ± 0.1
"	21	"	32.0 ± 0.4	32.1 ± 0.2	32.0 ± 0.1	32.3 ± 0.2
"	37	"	32.5 ± 0.1	32.3 ± 0.2	32.4 ± 0.1	32.6 ± 0.3

[0231] From the data of Table 5 it is clear that the experimental compounds 2, 15, 21, 37 according to the invention in doses 15.0, 30.0, 60.0 mg/kg do not affect the PATT.

4.2. The Effect on Prothrombin Time.

[0232] The "prothrombin time" is an important indicator of the hemostasis condition, which is widely used in experimental and clinical medicine.

[0233] The method of its determination is based on estimation of the coagulation of citrate or oxalic blood plasma, when it is mixed with thromboplastin and a calcium chloride solution. Since under these conditions the time of formation of the clot depends on the content of II, VII, IX and X factors in the investigated plasma sample, now the test is called "thromboplastin time by Quick" or "activity thromboplastin complex".

[0234] Compounds 2, 15, 21, 37 according to the invention at a concentration of 15, 30 and 60 mg/kg were administered to the above experimental animals intravenously and their blood was taken off after 15, 30, 60 and 120 minutes after the administration.

[0235] Citrate blood containing 1 part of citrate per 9 parts of native blood was centrifuged at 3000 rev/min for 10 minutes to obtain plasma deprived of thrombocytes.

[0236] Added into a test tube in a water bath were 0.1 ml of plasma and 0.1 ml of a thromboplastin solution. After 60 seconds, 0.1 ml of 0.277% solution of calcium chloride was added and the time of reaction T_i in seconds was registered. The results of the tests are given in Table 6.

TABLE 6

The effect of the compounds according to the invention on the prothrombin time of rabbits with intravenous administration of the compounds

T, s Control	Compound	Dose, mg/kg	T, s after 15 minutes.	T, s after 30 minutes.	T, s after 60 minutes.	T, s After 120 minutes
11.8 ± 0.1	2	15.0	11.7 ± 0.2	11.5 ± 0.2	11.4 ± 0.2	11.7 ± 0.1
"	15	"	11.5 ± 0.2	11.7 ± 0.2	11.2 ± 0.2	11.5 ± 0.2
"	21	"	11.4 ± 0.2	11.5 ± 0.1	11.3 ± 0.1	11.5 ± 0.2
"	37	"	11.6 ± 0.2	11.6 ± 0.1	11.3 ± 0.2	11.8 ± 0.1
11.2 ± 0.1	2	30.0	11.1 ± 0.2	11.0 ± 0.1	11.3 ± 0.1	11.2 ± 0.2
"	15	"	11.0 ± 0.2	11.2 ± 0.2	11.4 ± 0.2	11.3 ± 0.2
"	21	"	11.2 ± 0.1	11.2 ± 0.1	11.3 ± 0.2	11.2 ± 0.2
"	37	"	11.3 ± 0.1	11.2 ± 0.2	11.4 ± 0.1	11.1 ± 0.1
12.0 ± 0.1	2	60.0	12.0 ± 0.1	11.9 ± 0.2	12.1 ± 0.2	11.9 ± 0.1
"	15	"	12.0 ± 0.1	12.0 ± 0.1	12.0 ± 0.2	12.0 ± 0.1
"	21	"	12.0 ± 0.2	11.8 ± 0.1	12.1 ± 0.1	12.0 ± 0.2
"	37	"	12.1 ± 0.1	12.0 ± 0.1	12.1 ± 0.2	12.0 ± 0.1

[0237] From the data given in Table 6 it is evident that investigated compounds 2, 15, 21, 37 according to the invention taken in doses of 15.0, 30.0, 60.0 mg/kg have no effect on the prothrombin time index.

4.3. The Effect of Autocoagulation Test on Blood

[0238] This parameter characterizes the dynamics of increase and subsequent inactivation of the thromboplastin-thrombin activity of the blood being investigated.

[0239] Compounds 2, 15, 21, 37 according to the invention at a concentration of 15, 30 and 60 mg/kg were intravenously administered to the above experimental animals and their blood samples were taken off 15, 30, 60 and 120 minutes after the administration.

[0240] Added to 0.2 ml of plasma obtained by centrifuging citrate blood at 1500 rev/min within 10 minutes was a glycosilate-calcium mixture (2.0 ml 0.222% $CaCl_2$+0.1 ml of investigated citrate blood) 4, 6, 8, 10 minutes after the preparation of this mixture and the time of coagulation in the sample was determined.

[0241] The obtained results in seconds were translated in factors of coagulating activity A in percent, which specify the state of both the coagulating and anticoagulating parts of the blood coagulating system. The results of the experiments are given in Table 7.

TABLE 7

The effect of the compounds according to the invention on the values of coagulating activity A by the data of autocoagulation test with intravenous administration of the compounds to the rabbits

A, % Control	Compound	Dose, mg/kg	A, % after 15 minutes	A, % after 30 minutes	A, % after 60 minutes	A, % after 120 minutes.
85.6	2	15.0	80.2	100.0	87.4	98.0
"	15	"	82.3	103.0	89.0	101.2
"	21	"	81.4	101.3	86.5	97.4
"	37	"	82.1	102.8	88.7	100.6
70.0	2	30.0	98.4	71.2	104.2	70.9
"	15	"	100.3	68.4	106.6	70.6
"	21	"	97.2	69.1	103.7	71.0
"	37	"	99.8	68.3	105.8	70.4
65.9	2	60.0	72.3	60.8	62.5	65.7
"	15	"	74.4	63.2	64.4	66.5
"	21	"	71.9	62.1	63.7	66.2
"	37	"	74.3	63.0	64.2	66.3

[0242] From the data given in Table 7 it is evident that the investigated compounds 2, 15, 21, 37 according to the invention in doses 15.0, 30.0, 60.0 mg/kg have no effect on the coagulation activity according to the data of the autocoagulation test.

4.4. Effect on the Thrombin Time

[0243] The "thrombin time" characterizes the rate of transformation of fibrinogen into fibrin. It was determined by measuring the coagulation time of plasma deprived of thrombocytes under the effect of thrombin standardized by the control plasma.

[0244] 0.2 ml of a thrombin solution was added to 0.2 ml of the test blood plasma of experimental animals, from whom the blood was taken 15, 30, 60 and 120 minutes after the intravenous administration of compounds 2, 15, 21, 37 according to the invention in doses of 15, 30, 60 mg/kg incubated for 1 minute at a temperature of 37° C. and the time of formation of clot T_2 in seconds in a coagulometer of the Behnk Electronic Company (Germany). The test results are given in Table 8.

TABLE 8

The effect of the compounds according to the invention on the thrombin time of plasma of rabbits subjected to intravenous administration of the compounds

T_2, s Control	Compound	Dose, mg/kg	T_2, s after 15 minutes	T_2, s after 30 minutes	T_2, s after 60 minutes	T_2, s After 120 minutes
15.8	2	15.0	16.2*	17.0*	16.0*	15.3*
"	15	"	17.0*	18.5*	16.5*	15.5*
"	21	"	16.4*	17.7*	16.1*	15.7*
"	37	"	16.9*	18.2*	16.3*	15.6*
14.7	2	30.0	17.8*	18.4*	19.2*	15.1*
"	15	"	19.7*	20.5*	21.3*	15.0*
"	21	"	17.9*	18.8*	19.0*	15.6*
"	37	"	19.5*	20.3*	21.0*	15.2*
15.2	2	60.0	16.0*	16.9*	15.9*	15.3*
	15	"	16.8*	18.0*	16.5*	14.7*
	21	"	16.2*	17.7*	16.3*	15.7*
	37	"	16.6*	17.8*	16.2*	15.0*

Note:
*stands for a reliable value compared to the control at $p \leq 0.05$.

[0245] From the data, given in Table 8 it is evident that in a of dose 15.0 mg/kg the administration of the compounds according to the invention increases the thrombin time to the 15th minute of the observation, this effect reaching its maximum to the 30th minute, weakening during the following half an hour and completely disappearing to the 120th minute. Similar results were obtained with administration of the compounds in a dose of 60.0 mg/kg. The effect of the compounds on this hemostasis index increased only at a dose of 30.0 mg/kg: the blood clotting time was gradually enlarged within the first 25 minutes of the experiment, reaching the maximum to the 60th minute, and then was normalized to the 120th minute of the experiment.

Conclusions

[0246] The data obtained prove that the compounds according to the invention do not influence the pathological effect on a normally functioning hemostasis system.

5. The Effect of the Compounds According to the Invention on Processes of Production and Bonding of Active Forms of Oxygen.

[0247] The study of the effect of the compounds according to the invention on the activity of three most important oxidizing system enzymes of an organism: catalases, peroxidases and superoxydismutases was of great interest. These enzymes are accessible for determining in blood of human and animals and reflect three different levels of inactivation of active forms of oxygen: hydrogen peroxide, superoxidic radicals and intermediate forms of their exchange.

[0248] Free oxidation proceeds with participation of free-radical forms of oxygen, which are formed during one-electron reduction of oxygen and, first of all, superoxide-anion of oxygen radical O_2^-. This radical can be formed also at a change of conditions of functioning of a respiratory system and under effect of ultraviolet radiation, as well as during the reaction of oxygen with ions of metals of variable valence, mainly with iron Fe^{2+} and can be produced in the cells by enzymes, such, as xanthinexydase or NADPhH

oxydase. It is a highly reactive and hydrophilic compound that cannot abandon the cell and is collected in the cell cytosol.

[0249] The living cells have systems of protection against high production of free radicals. The enzyme superoxidedismutase SOD transforms superoxide-anion radical of oxygen into less reactive and more hydrophobic hydrogen peroxide H_2O_3. Hydrogen peroxide is a substrate for catalase and glutathione-dependent peroxidases which catalyze its transformation into molecules of water. An intensive generation of free radicals accompanies pathological condition, for example, the Parkinson's disease, Alzheimer's disease, and processes of biological aging. However, complete suppression of the peroxide processes in tissues is undesirable, because free radicals have useful properties. They induce apoptosis, participate in the formation of cellular immunity, adjust fatty-acid composition of lipide molecules in the cellular membrane.

[0250] It is well known that cyclic hydrazides of aromatic and heterocyclic orthodicarboxylic acids are capable of reacting with active forms of oxygen, in particular, with superoxide-anions, hydroxyl radicals and hydroperoxide radicals HO_2^- that is characterized by the phenomenon of chemiluminescence of said cyclic hydrazides (Brenton P. D. "Mechanistic Aspect of Diazaquinone Chemiluminescence. Aust. J. Chem., 1984, v. 37, p. 1001-1008).

[0251] The inventors have studied the capacity of the compounds according to the invention of penetrating through a cellular membrane and binding excessively produced superoxide-anions of oxygen.

5.1. The Effect of the Compounds According to the Invention on the SOD Activity of Bonding Superoxide-Anion Radicals.

[0252] The effect of the compounds according to the invention on the bonding of superoxide-anions of oxygen by superoxidismutase SOD was investigated.

[0253] The method is based on a competition of SOD or compounds according to the invention with nitroblue tetrazole (TTNB) for superoxide-anions formed during the aerobic reaction of NAD-H and phenosemetasulfate (FMS). It is known that in the presence of SOD the reduction of TTNB decreases. In the case of interaction of the compounds according to the invention with superoxide-anion radicals, the reduction of TTNB will also decrease (Nishikimi M. Rao N. A. and Yagi K. "The occurrence of superoxide anion in the reaction of reduced phenasine methosulfate and molecular oxygen". Biochem. Biophys. Res. Commun, 1972, v. 46, p. 849-855).

[0254] The process may be presented by the following scheme:

[0255] 1) NAD-H+ FMS→superoxide-anion radical+ NAD$^+$+reduced FMS

[0256] 2) SOD+superoxide-anion a radical→inactivated superoxide (or a compound according to the invention)

or TTNB+superoxide-aniou radical→reduced TTNB.

[0257] The intensity of generation and interception of a superoxide-anion radical was recorded at 560 HM by the degree of blocking the reaction of reduction of TTNB by the superoxidedismutase or investigated compounds. In so doing the activity of SOD or investigated compounds according to the invention was estimated taking 50% inhibition of reduced TTNB formation as a unit of activity. Depending on the effect of the compounds according to the invention, the SOD activity was expressed in units per minute on conversion to 1 mg of lysate of erythrocytes.

[0258] Erythrocytes of female mice of BALB/c line aged 3 months were washed with centrifuging and lysed with 10 volumes of distilled water. The hemolysate was then incubated for 30 minutes at 37° C. with compounds 3, 15, 23, 37 according to the invention at different concentrations, mkM: 10.0; 50.0; 100.0. The SOD activity was also measured.

[0259] The results of the experiments are presented on the graphs of FIG. **9**, where curves 1, 2, 3, 4 show the SOD activity A_{SOD} after incubation with compounds 3, 15, 23, 37, respectively.

[0260] From the graphs of FIG. **9** it is clear that the presence of the compounds according to the invention inhibits the SOD activity depending on the dose that is explained by competitive bonding of the superoxide-anion radicals by the compounds according to the invention.

5.2. The Effect on Production of Superoxide-Anion Radicals.

[0261] A possible effect of compounds 3, 15, 23, 37 according to the invention at concentrations of 10, 50, 100 mkM on the formation of superoxide-anion radicals in reaction NAD-H+ FMS+TTNB was investigated. This effect was estimated by a change of the optical density of the solutions during the formation of reduced TTNB.

[0262] HCT at a final concentration of 0.7 mM, FMS—33 mkM, NAD-H—70 mkM and the investigated compounds at different concentrations in the Henks solution were used. The reaction mass was incubated for 10 minutes at a temperature of 37° C. A change of the light-permeable capacity C of the reaction mixture was recorded in a spectrophotometer at 560 HM and was estimated in percent relative to an accepted light-pass standard in the model of reaction NAD-H+FMS+TTNB using, instead of the compounds according to the invention, SOD of erythrocytes 98% purity (recombinaut human SOD). The test results are given on the graphs of FIG. **10**, where curves 1, 2, 3, 4 illustrate the effect of the compounds 3, 15, 23, 37, respectively, on the SOD activity.

[0263] From the graphs in FIG. **10** it is evident that the investigated compounds can bind the formed superoxide-anion radicals depending on a dose used.

5.3. The Effect of the Compounds According to the Invention on the Catalase and Peroxidase Activity.

[0264] The methods of determining the catalase activity is based on quantitative determination of the rate of decomposition of hydrogen peroxide, which is a specific substrate for this enzyme. The processes of competitive interaction of compounds 3, 15, 23, 36 according to the invention with hydrogen peroxide were investigated.

[0265] To determine the catalase activity, the inventors used the method of spectrophotometric analysis of the products formed during the reaction of hydrogen peroxide with ammonium molybdate. This reaction is quick running and results in formation of stable products.

[0266] 2.0 ml of 0.03% hydrogen peroxide (standard) were added to 0.1 ml of homologinated erythrocytes of blood of mice, line BALB/c, or such a mixture was prepared with addition of one of compounds 3, 15, 23, 36 according to the invention at concentration of 1.0 or 10.0 mkg/ml (experiment) and then in different experiments 1.0 ml of 4% solution of a ammonium molybdate was added over 10, 20, 30, 60, 90, 120 minutes. The reaction is accompanied by fast and irreversible decomposition of the hydrogen peroxide with formation of colored products. The light absorption of the obtained solutions was measured at 410 nm. the test flask was 1 cm thick, distilled water being used in a control flask.

[0267] The results of the investigations are presented on the graphs of FIG. **11**, the catalase activity being expressed in relative values A_x. Curves 1, 2, 3, 4 illustrate the effect of compounds 3, 15, 23, 36, respectively, at a concentration of 1.0 mkg/ml on the catalase activity during time t of the experiment. The same dependence was observed for a concentration of 10.0 mkg/ml (not shown on the graph).

[0268] The measurement of the peroxidase activity is of considerable interest in clinical practice. For this purpose, use is made of a method based on oxidation of indigo carmine in ascent medium.

[0269] Added to 2.0 ml of and acetate buffer solution was 0.1 ml of homologinated erythrocytes of blood of mice, line BALB/c, then 2.0 ml of 0.03% hydrogen peroxide (control) solution was added to the mixture or the same mixture was prepared with addition of compounds 3, 15, 23, 36 according to the invention at a concentration of 1.0 or 10.0 mkg/ml (experiment). After that in different experiments 1.0 ml of indigo carmine was added to the mixture over 10, 20, 30, 60, 90, 120 minutes. The time of reaction with indigo carmine was recorded in seconds by a change of the solution color from dark blue through green in colorless and then in pink. In the experiments the time of the end of the reaction was fixed when the color transformed into colorless.

[0270] The obtained results are presented in relative values A_p on the graphs in FIG. **12** by curves 1, 2, 3, 4 for compounds 3, 15, 23, 36 according to the invention at a concentration of 1.0 mkg/ml, a similar dependence being observed for a concentration of 10.0 mkg/ml (not shown on the graphs).

Conclusions

[0271] Thus, the compounds according to the invention have a pronounced effect on the activity of the most important enzymes of the oxidizing system of an organism, i.e. catalase, peroxidase and superdismutase. In so doing the effect on the kinetics of the enzymes is of an oscillatory character with a limited amplitude, and this points to a regulatory action on the compounds according to the invention and transfer of the enzymes to a regime of active adaptation to the new conditions. Besides, it has been found that the compounds according to the invention are capable of reacting with excessive oxygen produced in the cell.

6. The Effect of the Compounds According to the Inventionon Development of Oxidizing Stress.

[0272] It is well known that under the oxidizing stress conditions raised due to excessive formation of active forms of oxygen or highly reactive nitrogen metabolites, many biochemical characteristics of blood in the cell change and nitrergic mechanisms of the cells are distorted.

[0273] The model of morphine abstinence in rats, which is an analogue of heroin abstinence of a human being was taken as a model of creation of an oxidizing stress in cells.

[0274] The physical dependence on morphine was simulated on male rats Wistar with a mass of 250-350 grams and aged 6 months by intraperitoneal administration of morphine with hydrochloride within 6 days, 2 times a day (at 10^{00} and 20^{00}) in increasing doses according to the scheme, mg/kg: 10,10; 20,20; 40,40; 60,60; 80,80; 100,100 (Rahman S., Ali Khan R., Kumar A. "Experimental study of the morphine deaddiction properties of Delphinium denudatum Wall// BMC Complement Altern". Med. 2002, v. 29, p. 1-6; Dum J., Blasig J., Herz A. Buprenorphine: "Demonstration of physical dependence liability". Eur. J. Pharmacol., 1981, v. 70. p. 293-300).

[0275] The experiments were carried out on rats in series of 7 animals on each compound according to the invention. Non-morphinized animal with not administered with compounds according to the invention were used as a control group. The first experimental group consisted of animals morphinized by the above-described technique, the second group consisted of animals treated with compounds 6, 15, 25, 37 according to the invention by intramuscular injection in a dose of 20.0 mg/kg three times a day, the third group consisted of morphinized animals, which three times a day following the last dose of morphine injection, were administered with compounds 6, 15, 25, 37 according to the invention intramuscularly in a dose of 20.0 mg/kg. Then the rats were decapitated, the blood from somnolent arteries was collected in test tubes with solution EDTA as an anticoagulant, centrifuged at 1500 g for 15 minutes at 4° C.

6.1. The Effect of the Compounds According to the Invention on the Activity of Enzymes in Blood Plasma

[0276] To estimate possible hepatoprotective action of the compounds according to the invention under conditions of development of an oxidizing stress in the liver cells, effect of these compounds on the most important biochemical blood indexes, in particular, on the content in blood plasma of indicator enzyme of aspartateaminotransferase (AST), alanineaminotransferase (ALT), γ-glutamiletranspeptidase (γ-GTP) was investigated. The content of enzymes was estimated by their catalyzing activity in blood plasma.

[0277] It is well known that morphine abstinence results in increased activity of enzymes AST and γ-GTP in blood plasma that indicates to toxic action of morphine on the liver of the animals.

[0278] The activity of AST, ALT and γ-GTP was determined by means of diagnostic sets DiaSys, Germany. The results of the tests are given in Table 9.

TABLE 9

The effect of morphine and compounds according to the invention on the content of C_i of indicator enzymes in blood plasma

Enzyme	C_o, mE/l Control	C_i, mE/l control + Morphine	Compound	C_i, mE/l Control + compound	C_i, mE/l control + Morphine + Compound
ALT	106.76 ± 111.35	116.12 ± 110.44	6	114.5 ± 1.13	122.44 ± 2.01
			15	113.48 ± 2.39	121.08 ± 5.04
			25	115.27 ± 1.09	121.96 ± 3.4
			37	113.84 ± 2.0	120.84 ± 5.20
AST	179 881 ± 11.94	238.201 ± 14.71	6	176.18 ± 3.26	198.34 ± 9.32
			15	173.46 ± 5.63	195.57 ± 18.68
			25	177.34 ± 6.13	196.46 ± 15.34
			37	174.82 ± 4.91	193.58 ± 14.18
γ-GTP	6.261 ± 1.80	16.80 ± 13.32	6	8.27 ± 2.12	12.52 ± 2.02
			15	7.03 ± 2.82	10.69 ± 1.84
			25	7.57 ± 1.93	11.37 ± 1.54
			37	8.14 ± 2.64	10.32 ± 2.67

[0279] From the data given in Table 9 it is evident that during the administration of the compounds according to the invention the activity of enzymes AST and γ-GTP did not change and conforms to the indexes of the control group. The administration of morphine resulted in an increase of the activity of said enzymes in blood that indicates to disturbance of the liver activity. The subsequent administration of the compounds according to the invention resulted in normalization of the liver activity and elimination of the consequences of the action of morphine on the cells of the rat liver.

6.2. The Effect of the Compounds According to the Invention on Endocellular Metabolic Processes

[0280] To estimate the intensity of metabolism of nitrogen oxide in rats, quantitative determination of stable metabolites of nitrogen oxide—nitrites and nitrates NO_X^- in the blood plasma, supernatanates of the liver and thymus gland, a study was conducted by a spectrometric method, and in the brain supernatanates by a photofluorographic method.

[0281] The spectrometric method is based the reaction of nitrites with the Griss reagent (a mixture of 2% solution of sulfanilamide and 0.2% N-(1-naphthyl)ethylene diamine. At the first step the nitrite reacts with sulfanilamide with formation of diazonium salt, and then with the second component to form azo dye with an adsorption maximum at 540 nm. For reduction of nitrates into nitrites, a fermentative method was used with bacterial reductase nitrate (Grisham M. B. et al., 1995). The samples of plasma and supernatant of the liver deproteinizated at 100° C. for 5 minutes incubated for 30 minutes at 37° C. in 50.0 mM of HEPES pH 7.4 in the presence of 0.2 unit/ml of Aspergillus reductase nitrate, 5.0 mkM of FAD and 0.1 mM of NAD-Ph. At the end of the reaction lactate dehydrogenase and pyruvate were added for isolation of NAD-Ph interfering with the Griss reaction. Then the Griss reagent was added and after 10-minute incubation the light absorption of the samples was measured at 540 nm. To amount of NO_X^- was calculated using sodium nitrate as a standard.

[0282] The fluorometric method is based on calculation of the nitrite level by the intensity fluorescence of 2,3-diaminonaphthotriazole, a product of reaction of 2,3-diaminonaphthalene (DAN) and nitrite in an acidic medium (Misko T. R., Schilling R. J., Salvemini D. et al. "A fluorometric assay for the measurement of nitrite of biological samples". Anal. Biochem., 1993, v. 214, p. 11-16). The brain supernatants deproteinizated at 100° C. were placed in a nitrite regenerating system containing 0.125 unit/ml of nitrate reductases, 25 mkM NADPh and 25 mkM FAD prepared in a 20-mM Tris-HCl buffer with pH 7.6 and incubated for 30 minutes at 37° C. The lactatedehydrogenase/pyruvate system was used for oxidation of the NADPh. Then 316 mkM of the DAN solution in 0.62 M of hydrochloric acids were added and the mixture was incubated for 10 minutes in darkness.

[0283] 280 mM of NaOH were added for stabilization of the fluorescence of the formed 2,3-diaminonaphthotriazole. The fluorescence intensity was measured in the spectrofluorimeter Hitachi F-3000 at a wavelength of excitation of 365 nm and an emission of 405 nm. The concentration of NO_X^- in the brain was calculated by means of a standard solution of sodium nitrate.

[0284] The effect of compounds 6, 15, 25, 37 according to the invention on the activity of isoform of synthase of nitrogen oxide (NOC) was also studied, in particular, on the activity of Ca^{2+} (independent) and Ca^{2+} (dependent) isoform NOC in the liver of morphinized rats by the radiometric method on the basis of the rate of accumulation of L-citrulline in an oxidation reaction [^{3}H]-arginine catalyzed by NOC (Bredt and Snyder. "Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum". Proc. Natl. Acad. Sci. USA, 1989, v. 86, p. 9030-9033). The formation of L-citrulline in this reaction is equivalent to biosynthesis of nitrogen oxide.

[0285] The reaction was initiated by adding supernatant of liver, brain or thymus in a reaction medium containing 2.0 mkKu/ml [^{3}H]L-arginine, 20 mM of HEPES pH 7.4, 0.2 mM of $CaCl_2$, 5.0 mkM of FAD, 5.0 mkM of FMN, 1.0 mM of NADPh, 50.0 mkM of BH_4 during the study of supernatants of the brain, while during the analysis of supernatants of the liver for inhibition of arginase and recycling of [^{3}H]L-citrulline in [^{3}H]L-arginine, the medium was mixed with 50.0 mM L-valine and 1.0 mM L-citrulline. After 15-60 minutes of incubation at 37° C., the samples were added with suspension Dowex 50WX8-400 (Na^+-form), which

sorbs unreacted L-arginine but not L-citrulline. After the sorption, the activity of the samples was determined on the scintillation counter SL-4000 "Intertechnique". The activity of Ca^{2+}-dependent and Ca^{2+}-independent isoform NOC was determined by a difference of the rates of formation of [^{3}H]L-citrulline in three parallel samples containing 2.0 mM of EDTA as a chelator of Ca^{2+} and as an inhibitor of all forms of NOC—2.0 mM of EDTAM L-NAME, and without inhibitors. The activity of enzyme NOC in the investigated supernatant was counted in pmol of [^{3}H]L-citrulline accumulated per unit of time on 1 mg of protein in the supernatant.

[0286] The results of the tests are given in Table 10 and in FIG. **13**.

TABLE 10

The effect of morphine and compounds according to the invention on the level of nitrites in blood plasma and supernatants of liver and brain and the activity of synthase of nitrogen oxide (NOC) in a brain

Index	Control	Control + Morphine	Compound	Control + Compound	Control + Morphine + compound
Nitrites in blood plasma, mkmol/ml	18.30 ± 2.14	12.12 ± 0.61	6	15.83 ± 1.21	15.86 ± 1.20
			15	14.39 ± 0.84	13.91 ± 1.91
			25	17.10 ± 2.05	16.78 ± 2.11
			37	16.13 ± 1.80	15.33 ± 0.87
Nitrites in liver, nmol/mg of protein	0.260 ± 0.023	0.259 ± 0.012	6	0.245 ± 0.010	0.294 ± 0.02
			15	0.259 ± 0.019	0.285 ± 0.02
			25	0.307 ± 0.012	0.287 ± 0.01
			37	0.262 ± 0.018	0.274 ± 0.01
Nitrites in brain, nmol/mg of protein:					
Cortex of cerebrum	4.63 ± 0.29	5.31 ± 0.29	6	4.59 ± 0.44	5.12 ± 0.18
			15	4.31 ± 0.37	4.72 ± 0.37
			25	4.47 ± 0.43	4.91 ± 0.32
			37	4.36 ± 0.24	4.77 ± 0.28
Mesencephalon	5.66 ± 0.19	9.41 ± 1.20	6	7.01 ± 0.82	5.76 ± 0.94
			15	6.65 ± 0.70	5.50 ± 0.43
			25	6.98 ± 1.02	5.91 ± 0.74
			37	6.84 ± 0.56	5.63 ± 0.37
Hypothalamus	6.57 ± 0.50	4.62 d 0.71	6	6.94 ± 0.67	6.72 ± 0.94
			15	6.77 ± 0.83	6.57 ± 0.88
			25	6.87 ± 0.80	6.67 ± 0.79
			37	6.79 ± 0.92	6.52 ± 0.83
Activity of NOC, pmol/min/mg of protein:					
Mesencephalon	2.18 ± 0.09	3.08 ± 0.09	6	2.84 ± 0.31	1.99 ± 0.31
			15	2.60 ± 0.29	1.83 ± 0.23
			25	2.65 ± 0.43	1.97 ± 0.27
			37	2.62 ± 0.27	1.85 ± 0.30
Hypothalamus	5.37 ± 0.20	3.42 ± 0.54	6	5.93 ± 0.27	5.24 ± 0.24
			15	5.45 ± 0.24	5.26 ± 0.28
			25	5.88 ± 0.27	5.23 ± 0.27
			37	5.61 ± 0.22	5.59 ± 0.22

[0287] From the levels of content of nitrites in blood given in Table 10 it is evident that morphine actually decreased the penetration of nitrites in the blood (at $p \leq 0.02$), and such a decrease of nitrites in blood may be an evidence of a decrease of generation of nitrogen oxide in organs or vessels at morphine abstinence. The compounds according to the invention prevented this effect that can confirm the effect of these compounds on the activity nitrogen oxide synthase in tissues or on the activity of an appropriate enzyme in the vessel endothelia.

[0288] In the liver (Table 10) the compounds according to the invention prevented accumulation of peroxidate oxidation products.

[0289] In the brain (Table 10) the morphine introduced to the animals has a specific effect on the accumulation of nitrites and the NOC activity: a decrease of nitrergic factors in the hypothalamus and an increase of the same in the cortex of cerebrum and mesencephalon. When only the compounds according to the invention were administered, a decrease of nitrergic factors in the cortex of cerebrum and their increase in a hypothalmus were observed. The subsequent administration of the compounds according to the invention recovered the NOC activity, disturbed by the morphine, in the hypothalamus, mesencephalon, and cortex of cerebrum.

[0290] Illustrated on the chart of FIG. **14** is the total NOC activity (field 1 of chart), the activity of the calcium-dependent NOC (field 2) and the activity of the calcium-independent NOC (field 3) in the control (value K), with the administration of morphine (value M), with administration of compounds 6, 15, 23, 37 (group C), and administration of the compounds according to the invention after the admin-

istration of the morphine (group D), respectively, from left to right in fields 1, 2, 3, 4.

[0291] The results of the investigations allow one to make a conclusion that in the liver the activity of isoform NOC reliably changed under the effect of morphine. Compared to the control, the total NOC activity in the morphinized rats and the rats received the compounds according to the invention only did not change. However, the administration of morphine resulted in a rise of activity of the calcium-dependent form NOC and a decrease of activity of the calcium-independent form NOC. The administration of the compounds according to the invention to the morphinized animals resulted in normalization of the activity of the calcium-dependent NOC and in an increase of the activity of the calcium-indepenndent NOC above the initial level that rises total activity of the NOC enzyme.

[0292] The effect of the compounds according to the invention on the condition of the thymus of the rats was also investigated: a control group, an experimental group of morphinized animals and an experimental group of animals were first morphinized and then injected with the compounds according to the invention. The experiment was carried out similarly to that described above. The results are given in Table 11.

TABLE 11

The effect of morphine and compounds according to the invention on the thymus condition

Index	Control	Administration of morphine	Compound	Administration of compounds	Administration of morphine and compound
Thymus mass, mg	230 ± 14	145 ± 9	6	242 ± 17	207 ± 14
			15	298 ± 25	214 ± 12
			25	254 ± 14	218 ± 17
			37	263 ± 21	228 ± 15
Nitrites, nmol/mg of protein Supernatant	0.331 ± 0.041	0.511 ± 0.05	6	0.424 ± 0.04	0.419 ± 0.02
			15	0.407 ± 0.02	0.383 ± 0.02
			25	0.417 ± 0.02	0.396 ± 0.02
			37	0.410 ± 0.01	0.387 ± 0.01

[0293] From the data given in Table 11 it is evident that the morphine abstinence initiates involution of the thymus, and the compounds according to the invention completely prevent this effect of morphine. Besides, the compounds according to the invention prevent accumulation of nitrites in the thymus.

Conclusions

[0294] Thus we may come to a conclusion that the compounds according to the invention feature hepatoprotective action: they prevent rising of activity of the enzymes AST and γ-GTP and stop an oxidizing stress in a liver.

[0295] Besides, the compounds according to the invention prevent involution of a thymus, influence different isoforms of synthase of nitrogen oxide, thereby correcting disordered nitrergic mechanisms in a liver, sections of brain and thymus.

7. Estimation of the Total Toxic Action of the Compounds According to the Invention.

[0296] The total toxic action of the compounds according to the invention was studied in chronic experiments on rats by introducing preparations in the form of suppositories containing compounds according to the invention as an active ingredient: 5% of active ingredient in the suppository base obtained by molding in a water bath of grades H-15 aud W-35 in equal quantities.

[0297] The experiments were conducted on inbred rats. The experimental animals were selected in groups by a method of random sampling taking into account the body mass as a determining index; 24 males or 24 females for one preparation from compounds 2, 15, 23, 34, 37 investigated in one dose. 4-5 hours prior to a rectal administration of the preparation, the animals were deprived of feed and the manipulations with animals resulted in a reflex act of a defecation of the rectum cavity.

[0298] Two doses of preparations used in the experiments: 50 mg/kg and 500 mg/kg. Before the administration, the suppositories were softened by heating in a glass water bath at a temperature of 38-39° C., the soft mass was collected in tuberculin syringe in a volume of 1 ml, a needle with oliva was attached to the syringe, and the preparatory mass was introduced into the rectum of the animal for a depth of 1.5-2.0 cm. The animals of the control group were administered with sterile medical liquid paraffin in a volume corresponding to the volume of the investigated suppository. A complete course of administration of drugs to the animals was two months. A complex of laboratory diagnostic investigations was carried out one month after the beginning of the administration of the preparation to the animal—in a middle of the course (8 animals), two months after ending the course (8 animals) and three months after ending the recovery period of one month (8 animals). The mass of the body of the rats in the first month of administration of the preparation was determined weekly, and then once in two weeks. On the basis of the dynamics of an index of the mass of the animal body, the volume of preparation being administered was corrected taking into account the test dose. The results of investigations are given in Tables 12, 13 and 14.

TABLE 12

Indexes of peripheral blood of male rats after administration of the investigated drugs in suppositories on 1 and 2 months

Blood index	Control 1 month/2 months	Compound	Dose 50 mg/kg 1 month/2 months	Dose 500 mg/kg 1 month/2 months
Hemoglobin, Mmol/dm^3	10.5 ± 0.2/11.4 ± 0.2	2	10.5 ± 0.1/11.1 ± 0.1	10.6 ± 0.1/12.3 ± 0.3*
		15	10.6 ± 0.2/11.2 ± 0.1	10.6 ± 0.2/12.5 ± 0.4*
		23	10.7 ± 0.1/11.0 ± 0.1	10.7 ± 0.2/12.3 ± 0.3*
		34	10.6 ± 0.1/11.1 ± 0.2	10.6 ± 0.3/12.4 ± 0.4*
		37	10.5 ± 0.1/11.0 ± 0.1	10.6 ± 0.1/12.1 ± 0.4*
Erythrocytes, mln/mm^3	5.6 ± 0.1/6.1 ± 0.1	2	5.60 ± 2/6.1 + 0.1	5.6 ± 0.1/6.5 ± 0.1*
		15	5.7 ± 0.2/6.0 ± 0.1	5.7 ± 0.1/6.7 ± 0.2*
		23	5.7 ± 0.1/6.0 ± 0.2	5.7 ± 0.2/6.4 ± 0.2*
		34	5.6 ± 0.1/6.1 ± 0.2	5.6 ± 0.2/6.6 ± 0.1*
		37	5.6 ± 0.2/6.2 + 0.1	5.7 ± 0.1/6.5 ± 0.2*
Haematocrite, %	45.9 ± 1.7/45.9 ± 1.8	2	47.8 ± 1.3/47.9 ± 1.5	47.3 ± 1.6/50.3 + 2.0
		15	47.9 ± 1.4/47.5 ± 1.2	47.6 ± 1.3/53.9 ± 2.1*
		23	47.7 ± 1.2/46.5 ± 1.3	47.9 ± 1.1/49.4 ± 1.9*
		34	46.9 ± 1.1/47.5 ± 1.2	48.1 ± 1.5/53.1 ± 1.6*
		37	47.8 ± 1.4/47.5 ± 1.2	47.9 ± 1.8/52.5 ± 1.7*
Average volume of erythrocytes, Mkm^3	81.4 ± 1.7/74.6 ± 1.9	2	83.4 ± 1.4/77.9 ± 2.1	85.2 ± 1.2/72.0 ± 2.5*
		15	84.4 ± 1.5/78.6 ± 1.5	82.6 ± 1.1/80.21 ± 1.2*
		23	82.7 ± 1.6/77.5 ± 1.7	83.5 ± 1.7/82.1 ± 1.4*
		34	81.6 ± 1.9/76.7 ± 1.9	84.1 ± 1.3/83.8 ± 1.5*
		37	83.9 ± 1.7/78.5 ± 1.4	82.5 ± 1.5/80.1 ± 1.0*
Reticulocytes, %	2.8% 0.3/2.9 ± 0.2	2	2.8 ± 0.2/2.8 ± 0.2	2.9 ± 0.3/3.5 ± 0.2
		15	2.6 ± 0.2/3.0 ± 0.1	3.1 ± 0.2/3.3 ± 0.3
		23	2.7 ± 0.3/2.8 ± 0.1	3.1 ± 0.1/3.4 ± 0.1
		34	2.7 ± 0.1/2.9 ± 0.2	3.2 ± 0.2/3.5 ± 0.3
		37	2.6 ± 0.1/3.1 ± 0.1	3.0 ± 0.2/3.4 ± 0.2
Thrombocytes, %	707 ± 23/393 ± 14	2	659 ± 26/566 ± 20	681 ± 26/583 ± 25
		15	678 ± 13/597 ± 24	683 ± 14/616 ± 40
		23	659 ± 18/586 ± 28	678 ± 18/628 ± 23
		34	670 ± 23/610 ± 15	682 ± 24/631 ± 26
		37	675 ± 22/609 ± 18	671 ± 126/639 ± 34
Coagulation, time, seconds	152 ± 10.2/316 ± 8	2	145 ± 16/322 ± 18	149 ± 11/305 ± 13
		15	140 ± 12.2/321 ± 12	151 ± 6.4/308 ± 16
		23	150 ± 15/313 ± 17	156 ± 11/317 ± 12
		34	148 ± 16/321 ± 10	165% 10/312 ± 9
		37	151 ± 13/319 ± 12	157 ± 14/3161 ± 14
REE, mm/h	2.2 ± 0.4/1.4 ± 0.2	2	1.9 ± 0.3/1.7 ± 0.1	2.1 ± 0.3/1.9 ± 0.1
		15	1.8 ± 0.4/1.6 ± 0.2	2.2 ± 0.4/1.8 ± 0.4
		23	1.7 ± 0.8/1.5 ± 0.1	2.0 ± 0.3/1.7 ± 0.3
		34	1.8 ± 0.5/1.7 ± 0.3	2.0 ± 0.4/1.8 ± 0.2
		37	1.8 ± 0.3/1.6 ± 0.3	2.2 ± 0.3/2.0 ± 0.1
Leukocyte, thousand/mm^3	17.4 ± 1.3/19.1 ± 1.9	2	16.0 ± 1.4/19.3 ± 1.6	15.6 ± 0.8/18.6 ± 1.9
		15	14.8 ± 2.0/16.3 ± 1.0	17.0 ± 1.4/21.1 ± 2.4
		23	15.5 ± 1.1/17.6 ± 1.2	16.4 ± 1.1/20.1 ± 1.7
		34	15.9 ± 1.3/17.8 + 1.4	16.9 ± 1.0/22.1 ± 1.1
		37	14.9 ± 1.5/16.7 ± 1.2	17.1 ± 0.9/18.7 ± 1.7
Basophiles, %	0	2	0	0
		15	0	0
		23	0	0
		34	0	0
		37	0	0
Eosinophiles, %	4.0 + 0.3/4.4 + 1.2	2	3.4 ± 0.6/4.2 ± 0.8	3.2 ± 0.9/4.8 ± 1.6
		15	3.2 ± 1.0/3.6 ± 1.2	3.0 ± 1.0/3.2 ± 1.4
		23	3.6 ± 0.5/4.0 ± 0.7	3.3 ± 0.7/3.8 ± 1.3
		34	3.5 ± 1.0/4.1 ± 0.4	3.0 ± 0.9/3.9 ± 1.4
		37	3.8 ± 0.8/4.2 ± 0.3	3.5 ± 1.0/4.1 ± 1.3
Juveniles, %	0	2	0	0
		15	0	0
		23	0	0
		34	0	0
		37	0	0
Stab neutrophil %	0.8 ± 0.4/2.4 ± 0.4	2	0.8 ± 0.3/1.7 ± 0.3	0.9 ± 0.2/1.1 ± 0.3
		15	1.2 ± 0.5/0.8 ± 0.5	0.8 ± 0.5/0.8 ± 0.5
		23	1.1 ± 0.5/1.6 ± 0.2	1.0 ± 0.3/1.6 ± 0.2
		34	1.0 ± 0.4/1.8 ± 0.5	0.9 ± 0.2/1.4 ± 0.3
		37	1.3 ± 0.5/1.9 ± 0.4	0.9 ± 0.4/1.1 ± 0.6

[0299]

TABLE 13

The biochemical indexes of blood serum of male rats 1 month after administration of suppositories containing the compounds according to the invention

Index	Control	Compound	Dose 50 mg/kg	Dose 500 mg/kg
Total protein, g/l	94.89 ± 6.67	2	87.34 ± 5.56	70.84 ± 7.47
		15	90.22 ± 6.78	71.56 ± 8.23
		37	89.44 ± 7.22	70.88 ± 7.24
Glucose, mol/l	9.76 ± 0.15	2	9.85 ± 0.37	10.20 ± 0.74
		15	10.00 ± 0.41	10.71 ± 0.41
		37	9.9 ± 0.51	10.93 ± 0.84
Urea, Mkmol/l	8.44 ± 0.69	2	11.02 ± 0.73	11.30 ± 0.80
		15	10.33 + 0.51	10.89 ± 0.73
		37	9.36 ± 0.62	10.57 ± 0.56
Cholesterol, mmol/l	3.02 ± 0.68	2	2.77 ± 0.71	2.96 ± 0.52
		15	2.01 ± 0.50	2.30 ± 0.57
		37	2.48 ± 0.62	2.64 ± 0.46
Creatinine, mkmol/l	40.23 ± 2.84	2	47.38 ± 3.26	46.87 ± 8.12
		15	45.59 ± 2.68	48.27 ± 12.29
		37	46.84 ± 2.92	47.13 ± 9.82
ALT, unit/l	11.33 ± 1.96	2	10.84 ± 2.02	11.23 ± 1.70
		15	7.63 ± 1.95	9.48 ± 1.85
		37	8.98 ± 2.43	9.56 ± 1.34
AST, unit/l	19.13 ± 1.02	2	20.41 ± 3.06	20.13 ± 2.95
		15	19.49 ± 2.90	15.14 ± 1.58
		37	19.97 ± 2.78	18.21 ± 1.87
Alkalinous phosphatase, unit/l	40.74 ± 1.57	2	42.12 ± 4.23	43.4 ± 2.12
		15	40.74 ± 6.78	41.60 ± 2.26
		37	41.86 ± 5.26	42.18 ± 2.34
Bilirubin, mmol/l	38.93 ± 2.19	2	44.38 ± 4.12	42.56 ± 7.56
		15	43.67 ± 3.57	40.69 ± 15.75
		37	42.17 ± 3.28	41.45 ± 7.18

[0300]

TABLE 14

Indexes of urine of the rats 1 month after the administration of the compounds according to the invention in the form of suppositories

Index	Control	Compound	Dose 50 mg/kg	Dose 500 mg/kg
Protein, g/l	0.74 ± 0.26	2	0.69 ± 0.33	0.76 ± 0.31
		15	0.71 ± 0.274	0.87 ± 0.24
		37	0.70 ± 0.19	0.72 ± 0.14
Urea, mmol/l	472 ± 140	2	457 ± 144	492 ± 187
		15	413 ± 128	485 ± 131
		37	427 ± 137	489 ± 152
Glucose, Mmol/l	<6	2	<5	<5
		15	<6	<6
		37	<5	<5
Potassium, g/l	5.96 ± 1.1	2	5.78 ± 1.7	6.24 ± 1.8
		15	5.28 ± 1.5	6.13 ± 1.6
		37	6.12 ± 1.4	6.44 ± 1.3
Sodium, g/l	0.9 ± 0.1	2	1.7 ± 0.3	1.27 ± 0.3
		15	1.2 ± 0.4	0.64 ± 0.4
		37	1.4 ± 0.2	0.88 ± 0.4
Uro-bilinogen, Mkmol/l	<17	2	<16	<16
		15	<17	<17
		37	<15	<15
pH	6.2 ± 0.3	2	6.1 ± 0.3	6.2 ± 0.2
		15	6.3 ± 0.4	6.2 ± 0.3
		37	6.4 ± 0.4	6.2 ± 0.3
Bilirubin, Mkmol/l	<5	2	<5	<5
		15	<5	<5
		37	<5	<5
Ketone bodies Mmol/l	<1	2	<1	<1
		15	<1	<1
		37	<1	<1

[0301] In the course of administration of preparations all groups of animals irrespective of the preparation dose were in stable clinical state without any signs of intoxication; the appearance and behavioral reactions were usual for healthy rats, the consumption of feed and water corresponded to the physiological norm.

[0302] From the results of investigations given in Tables 12, 13, 14, it is evident that 1 month after the administration of the suppository compounds according to the invention no changes in the indexes of the peripheral blood of the animals were found. 2 months after the administration of the suppositories no reliable difference in the indexes of peripheral blood of the animas received suppositories in a dose of 50 mg/kg was found. Concerning the animals received suppositories in a dose of 500 mg/kg, some changes were found, in particular the total amount of erythrocytes, hemoglobin, haematocrite value and an average volume of erythrocytes, in some cases a decrease of time of blood coagulation compared to the control value was observed.

[0303] The study of the biochemical indexes of blood serum and urine after long-time administration of the compounds according to the invention in suppositories has not revealed any difference between experimeutal and control animals.

[0304] The pathologoanatomic study one month after the beginning of administration suppositories and upon termination of the complete course of the treatment have shown that during the postmortem examination an identical picture without features of pathology was found out: the woolen integument was sleek, bright; the hypodermic fatty tissue was moderately evident. The lungs—airy of a light pink

color, from the parenchyma section a small amount of a foamy reddish liquid flows down. The liver is elastic of a usual shape, the edges of the organ are slightly rounded, the capsule is sleek, bright, the tissue of the organ at the section is dark red, plethoric, bright. The kidneys are surrounded with a mild amount of fatty tissue, have beanlike shape, elastic, and the capsule is bright, clean and is easily taken out. The cortical and cerebral substance have a usual pattern with an expressed dividing boundary, the pelvis contains a small amount of a transparent, slightly opalescent liquid. The epinephroses are of a spherical shape, at the section are clearly differentiated in a lighter cortical substance and a dark cerebral substance. The spleen is elongated with a bright capsule, the pulp is of dark-cherry color, an insignificant amount of tissue and blood-like liquid being scrapable from the section surface. The thick intestine has a small amount of mucus with no signs of inflation, the vascular pattern is slightly expressed, the mucous tunic are clean without mucosal ulceration, the fecal mass in the end organ are formed. The testicles are of an oval shape of a dense consistence, with a slightly expressed vascular grid.

[0305] The dynamics of mass of the rat body during the administration of the preparations (1 to 9 weeks) was positive and did not differ from the dynamics in the control group.

[0306] The investigations were also aimed at the presence of irritating action of the suppositories on the mucosa of intestine and resorptive action: on rats with a mass of the organ of 169±7 g, the dose of 500 mg/kg being introduced ouce, the postmortem examination was made 30 minutes, 2 hours and 24 hours after the administration of the suppository. During the study of the rectum a small amount of mucus was found in the intestine lumen with the absence of an edema or hyperemia of the mucosa.

[0307] The irritating action of the suppositories on the eye mucosas was also studied on 5 rabbits of the chinchilla breed with a mass of 2.6 to 2.9 kg; the administration of a preparation in an amount of 75 mg at 37-38° C. into a lachrymal sac of one eye, and the effect was observed in 15, 30, 60 and 120 minutes after the administration and then for 24 hours. Any inflammatory phenomena were not found and there were no lachrymation, edemas or injections of the sclera vessels and conjunctiva.

[0308] In addition, the irritating action of the suppositories on the skin was determined: the preparation containing compounds according to the invention in suppository mass heated to 37-38° C. in an amount of 1000 mg was applied on skin sections sized 2×2 cm 10 of rats with a body mass of 175±6 g and 6 caves with a body mass of 235±17 g with a white wool. The duration of the application was 4 hours. Skin hyperlipemia, thickening of the skinfold or other features of irritation were not observed. During the application period and 24 hours after it no changes of the clinical state of the experimental animals was not found.

[0309] Thus, the absence of local irritation and toxic resorptive action of the preparations containing compounds according to the invention has not bee found during a single application in a considerable dose.

[0310] It should be clear for those skilled in the field of medicine and bioorganic chemistry that above-described properties of the compounds according to the invention can manifest themselves also in normalization of other processes arising in an organisms and associated with metabolic acidosis and an effect of an excessive quantity of free-radical forms of oxygen, in particular, uncontrollable inflammations, uncontrollable proteolysis, poor activity of the enzyme of helicase responding for untwisting the DNA duplex in a replicative zone of uncontrollable oxidation-reduction processes, processes of a premature aging of an organism effecting on the electronic-proton processes in the unitochondrion and on functioning of the respiratory system.

[0311] The application of the cyclic bioisosteres of derivatives of a purine system according to the invention or their pharmacologically acceptable salts as active ingredients of a pharmaceutical composition allows one to produce pharmaceutical compositions in a wide range of practical application.

[0312] In so doing they render normalizing effect on the vital systems of an organism, which can be predicted and chosen optimal depending on the indications, an amount of active ingredient in a medicinal preparation, a dose, and conditions of a drug intake.

[0313] Pharmaceutically acceptable salts of cyclic bioisosteres of derivatives of a purine system, according to the invention may be salts of pharmaceutically acceptable metals such as lithium, sodium, potassium, calcium, barium, silver, as well as salt pharmaceutically acceptable acids such as hydrochlorides, sulfases, acetases. hydrobromides, phosphases, succinates, maleates, fumarates, citrases, gluconates, methylsulphonates, n-toluenesulphonates. The pharmaceutically acceptable salts can be obtained by reacting cyclic bioisosteres of derivatives of a purine system with corresponding acids or bases.

[0314] The active ingredient of the pharmaceutical composition according to the invention may comprise a composition of several compounds according to the invention, for example, salts of alkaline and/or alkaline-earth metals, for example, a composition of sodium and potassium salts, sodium and lithium and others, which are well compatible among themselves and, depending on their biological activity, can increase the duration of action of the medicinal preparation in an organism.

[0315] The pharmaceutical composition based on the compounds according to the invention can be a solution of an active ingredient in pharmaceutically acceptable liquid carrier, for example, water, a physiological solution, buffer solutions or compatible with ingredients enhancing their solubility.

[0316] The pharmaceutical composition can represent can be a fine powder of an active ingredient suitable for application in solutions for injections, in applications or used for preparation of various medicinal forms.

[0317] The oral administration is usually a preferable way for administration of medicinal agents into an organism. as this way is the most convenient and acceptable for the patient. The compositions according to the invention can be made as agents for oral administration. for example, tablets, granules, globules, powders, capsules, ampoules, suspensions, emulsions. In so doing the pharmaceutical composition may in addition contain agents for rising bioavailability. for example, microcrystalline cellulose that allows one to reduce the contents of biologically active ingredient in a

single drug dose, or, besides, may be made as a spontaneously dispersed concentrate which, when mixed with distilled water or physiological solution of cooking salt, creates aqueous microemulsions with a stable phase and increased ability of infiltration and diffusion.

[0318] It is desirable in the treatment of acute states that the pharmaceutical composition has fast and consecutive action and good biological compatibility of the components of the composition and the medium.

[0319] The fast absorption of the active ingredient can be achieved by a parenteral injection that is traditional for clinical conditions but it is unacceptable for self-treatment. In this case, an effective way of administration of a medicinal agent in an organism through rectum using clusters, soft gelatinous capsules or suppositories, for example, as solid dosed forms with a suitable configuration which either melt at a human body temperature or are dissolved or disperse in the mucous secretion cavity. The cyclic bioisosteres of a derivative purine system according to the invention are well combined with known components and ingredients used for manufacture of medicinal preparations.

[0320] The medical experts know that for improvement of the adsorption of biologically active substances having poor solubility in water or in any selective media, the active ingredient of a pharmaceutical composition in the form of a saturated solution, in a solid form can be encapsulated in one or more plate membrane containing lipids, for example, in liposomes, allowing the active ingredient to be delivered to a specific region.

[0321] According to the invention, in the pharmaceutical composition derivatives of phthalhydrozines and their salts can be contained in a liposomal form, for example, in a multiphase liposom system of delivery of medicines, which is stable and can be easily diluted in water, varying the state of the pharmaceutical composition from a state of a diluted liquid up to a gelatinous state that is important for derivative compounds, which in the initial condition are poorly soluble in the gastrointestinal path medium, as well as expands a possibility of application of higher doses of the active ingredient to be introduced orally.

[0322] Besides in the pharmaceutical composition according to the invention the pharmaceutically the acceptable carrier may represent a composition containing pharmaceutically active additives.

[0323] In so doing, according to the invention, in the pharmacologically active additives may be selected from the group including stabilizing agents, dispensers, aromatizers, emulsifiers, conductors, bioavailability rising agents. one of which can be an agent for increasing solubility of not readily soluble compounds, for example, solvent of dimethylsulfoxide (DMSO).

[0324] In many diseases it is expedient to use different methods of local action on a pathological process, especially in presence of contraindication to general therapy, for example, at appreciable disorder of the vital organs. One of the methods of local treatment is application of external medicinal agents.

[0325] It is known that, proceeding from the skin sensitivity, probability of its irritation and transdermal absorptivity (skin hygroscopic capacity), pH of the pharmaceutical preparation for external application should be kept in a range of 4-8, preferably, in a range of 5-7. When pH is too low (pH 3 and lower), its high acidity initiates a strong skin irritation. When pH is too high (pH 9 and higher), the transdermal absorptivity of the active ingredient is reduced, the skin irritation rises up.

[0326] In order to increase the transdermal absorptivity (suction) of the active ingredient, the pharmaceutical preparation can be mixed with the so-called amplifiers of absorption, for example, organic bases such as triethanolamin, crotamiton, esters of fatty acids with an average chain length, 1-menthol, benzalcohol and similar substances. The organic base facilitates the release of the active ingredient from the base, because it makes the compound more water-soluble due to the formation of salts. The organic base acts as a regulator of pH of a medicinal preparation.

[0327] pH of a medicinal agent can also be adjusted by alkaline compounds (potassium hydroxide and sodium hydroxide, triethanolamin, diisopropanolamine, monoethanolamit, etc.

[0328] The solutions of the metal salts of the compounds according to the invention have pH=7-8, the solutions of hydrochlorides, acetates, phosphases, hydrobromides, nitrates, sulfases and other organic salts of the compounds according to the invention have pH=4-7 that provides good prospects of creation of medicinal agents for external application.

[0329] In so doing a pharmaceutical composition for external application may represent a gel-emulsion containing as an active ingredient a bioisostere derivative of a purine system according to the invention, hydrophylic polymer, oily substance, a nonionic surface-active agent, an alkaline compound or an organic base as a pH regulator of the medium and water. In this case, the bioisosteres of derivatives of a purine system according to the invention are chemically compatible with these ingredients.

[0330] The pharmaceutical composition according to the invention can be made, for example, in the form of a disappearing emulsion including higher alcohol, hydrocarbon, ester of fatty acid, polyol or alkali, an antiseptic agent, water and other ingredients.

[0331] The pharmaceutical compositions can be based on of the compounds according to the invention, for example, in the form of gels formed by means of gel-forming derivatives of cellulose, for example, oxyethylcellulose, oxypropylcellulose, carbooxymethylcellulose and other derivative containing starch, gelatine, synthetic polymers, for example, polyvinylpyrolidone, polyethyleneglycol, moistening agents such as polyatomic alcohols, for example, glycerin, 1,3-butyleneglycol, propyleneglycol, dipropyleneglycol, etc.

[0332] The pharmaceutical composition based on bioisosteres of derivatives of a purine system according to the invention can be hydrophylic ointment or water-absorbing ointment emulsion containing petrolatum oil, liquid paraffin, surface-active compounds, for example, esters of sorbitane and fatty acids (sorbitanemonostearate and ethers), esters of glycerin and fatty acids (glycerylmonostearate, diglycerylmonooleate, etc), esters of polyoxyethylenesorbitane and

fatty acids (polyoxyethylenemonostearate and others), esters of polyethylene glycol and fatty acids, polyethylene hydrogenized castoric oil, mixture of these substances, and other components, for example, higher alcohol such as hydrocarbon, for example, paraffin, ceresine, cetyl alcohol (cetanol), stearyl alcohol, oleyl alcohol, behenolic alcohol, ethers of a fatty acid, for example, stearin, oleic, polyatomic alcohol, oil and vegetable fats, for example, olive, castoric oil, animal fats (beef and pork lard, horse fat and other fats), mineral wax, beeswax, as well as antiseptic, for example, methylparaben, propylparaben and water.

INDUSTRIAL APPLICABILITY

[0333] The application of cyclic bioisosteres of derivatives of a purine system according to the invention or their pharmacologically acceptable salts as active ingredients of a pharmaceutical composition allows one to produce pharmaceutical compositions of a wide range of application with the use of the therapeutic effect caused by the inherent properties of the cyclic bioisosteres of a purine system according to the invention.

1. The use of a layer (HIL 1) composed of a hydrophobic, linearly or two-dimensionally polycyclic aromatic having from 3 to 12 ring structures including metal-containing or metal-free phthalocyanines, which have, as radical groups, —H and/or —F, alkyl groups, aryl groups and/or fluorinated hydrocarbons, as a barrier layer in or as an encapsulation of electrical components constructed with organic layers.

2. The use as claimed in claim 1, wherein the layer has been formed from a material selected from the group consisting of anthracene, phenanthrene, tetracene, chrysene, pentacene, hexacene, perylene, triphenylene, coronene, m-napthhodianthracene, pyrene, benzopyrene, ovalene, violanthrene, and derivatives of the aforementioned substances, with radical groups —H and/or —F, alkyl groups, aryl groups and/or fluorinated hydrocarbons.

3. The use as claimed in claim 1, wherein the layer is formed from a metal-containing phthalocyanine of the formula:



where M is any of Cu, Zn, Fe, Mn, Co, or Ni, and each R may be an —H and/or —F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

4. The use as claimed in claim 1, wherein the layer is formed from a metal-fee phthalocyanine of the formula:



where each R may be an —H and/or —F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

5. An organic light-emitting diode having a substrate, a first electrode applied to the substrate, at least one electron-injecting and -transporting zone (EIL), at least one hole-injecting and -transporting zone (HTL, HIL) and a second electrode wherein the hole-injecting and -transporting zone includes a layer composed of polycyclic aromatics having linear or two-dimensional chains and from 3 to 12 ring structures including metal-containing or metal-free phthalocyanines, which have, as radical groups, —H and/or —F, alkyl groups, aryl groups, and or fluorinated hydrocarbons, said layer being in the form of an encapsulation layer.

6. An organic light-emitting diode having a substrate, a cathode applied to the substrate, at least one electron-injecting and -transporting zone (EIL), at least one hole-injecting and -transporting zone (HTL, HIL), and a light-transparent anode wherein the electron-injecting and -transporting zone (EIL) is constructed with small molecules, and wherein said electron-injecting and -transporting zone (EIL) is adjoined toward the anode by a layer composed of polycyclic aromatics having linear or two-dimensional chains and from 3 to 12 ring structures including metal-containing or metal-free phthalocyanines, which includes, as radical groups —H and/or —F, alkyl groups, aryl groups and/or fluorinated hydrocarbons.

7. The organic light-emitting diode as claimed in claim 5, in which the material of the layer is formed from substances of the group consisting of anthracene, phenanthrene, tetracene, chrysene, pentacene, hexacene, perylene, triphenylene, coronene, m-napthodianthracene, m-anthraceneoditetracene, m-tetracenodipentacene, pyrene, benzopyrene, ovalene, violanthrene and derivatives of the aforementioned substances with radical groups —H and/or —F, alkyl groups, aryl groups and/or fluorinated hydrocarbons.

8. The organic light-emitting diode as claimed in claim 5, in which the layer is formed from a metal-containing phthalocyanine of the formula



where M is any of Cu, Zn, Fe, Mn, Co, or Ni, and each R may be an —H and/or —F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

9. The organic light-emitting diode as claimed in claim 5, in which the layer is formed from a metal-free phthalocyanine of the formula



where each R may be an —H and/or —F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

10. The organic light-emitting diode as claimed in claim 5 wherein a hole-injecting and -transporting polymer layer (HIL 2) applied from aqueous solution has been applied between the layer (HIL 1) and the second electrode.

11. The organic light-emitting diode as claimed in claim 6 in which the material of the layer is formed from substances of the group consisting of anthracene, phenanthrene, tetracene, chrysene, pentacene, hexacene, perylene, triphenylene, coronene, m-naphthodianthracene, m-anthraceneo-ditetracene, m-tetracenodipentacene, pyrene, benzopyrene, ovalene, violanthrene and derivatives of the aforementioned substances with radical groups —H and/or —F, alkyl groups, aryl groups and/or fluorinated hydrocarbons.

12. The organic light-emitting diode as claimed in claim 6, in which the layer is formed from a metal-containing phthalocyanine of the formula



where M is any of Cu, Zn, Fe, Mn, Co, or Ni, and each R may be an —H and/or —F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

13. The organic light-emitting diode as claimed in claim 6, in which the layer is formed from a metal-free phthalocyanine of the formula



where each R may be an —H and/or —F and/or an alkyl group and/or an aryl group and/or a fluorinated hydrocarbon.

14. The organic light-emitting diode as claimed in claim 7 wherein a hole-injecting and -transporting polymer layer (HIL 2) applied from aqueous solution has been applied between the layer (HIL 1) and the second electrode.

15. The organic light-emitting diode as claimed in claim 8 wherein a hole-injecting and -transporting polymer layer (HIL 2) applied from aqueous solution has been applied between the layer (HIL 1) and the second electrode.

16. The organic light-emitting diode as claimed in claim 9 wherein a hole-injecting and -transporting polymer layer (HIL 2) applied from aqueous solution has been applied between the layer (HIL 1) and the second electrode.

* * * * *